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Abstract 
 
Molecular chaperones are indispensable cellular components that assist folding and 
assembly of newly synthesized proteins, translocation of proteins across 
membranes, as well as refolding and degrading of misfolded and aggregated 
proteins. In the last few years, innovative therapeutic strategies targeting stability 
and functionality of chaperones have received great attention, particularly in the 
field of neurodegenerative diseases. Moreover, the growing number of diseases 
found linked to chaperone mutations, testifies to the importance of their role in the 
cellular protein-quality control mechanism. The investigation of the biophysical 
interactions between chaperones and specific proteins involved in diseases, 
including their structural and functional properties, are therefore a crucial step for 
both validating the chaperones’ role in physiological and pathological state, and 
developing effective chaperones-based treatment approaches. 
In the present PhD thesis work, we studied two representative examples of human 
molecular chaperones, Hsp60 and CCT/TRiC, appertaining to the class of the so-
called “chaperonins” (Cpns). They are large, hollow, ATP-dependent 
nanomachines that promote correct folding of a wide range of proteins. 
 Heat shock protein (Hsp60) is a molecular chaperone that assists protein folding in 
mitochondria. Hsp60 can accumulate in the cytosol, in various pathological 
conditions (i.e., cancer and chronic inflammatory diseases). Here we studied its 
functional oligomeric equilibrium as compared to that of its well-known bacterial 
homolog GroEL. We also show that Hsp60 is capable of inhibiting the 
fibrillogenesis of Aβ peptide (the protein involved in Alzheimer’s disease). The 
probable inhibition mechanism operating at molecular level is discussed. 
CCT/TriC is a chaperon universally found in Archaea and eukaryotes. Several 
chaperonopathies linked to CCT loci are clinically well characterized and, for those 
due to non-lethal genetic mutations, there is considerable information on their mode 
of inheritance. 
A protein model has been recently developed to investigate the mechanism of a 
crippling hereditary sensory neuropathy, due to a point mutation (His147Arg) in 
CCT5, one of the eight subunits of the human CCT. Here we report quantitative 
information on the loss of structural stability impaired by the pathogenic mutation. 
 
 
  Dario Spigolon 
 
 Biophysical investigation on therapeutic proteins (Chaperonins, Hsp60 and CCT/TRiC) involved in human diseases 
Finally, we tested if an eﬃcient inhibition of amyloid formation can be achieved by 
chaperone-like systems, like as α-Caseins, which is known to exert a stabilizing 
function through direct interaction (similar to small Hsps).  In fact, the evaluation 
of the mechanism of chaperone-like activity proved helpful for better understanding 
the structural basis of the substrate binding in sHsps. 
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Chapter I      
“Molecular chaperones” 
 
1.1 Introduction 
 
About 60 years ago, Anfinsen demonstrated that a polypeptide chains fold 
spontaneously to form native, compact protein structures whose three-dimensional 
conformation is determined by the amino acids sequence. This result was the basis 
of a fundamental principle of biology, the Anfinsen’s paradigm [1.1], stating that 
the native structure of a protein is encoded in its primary structure.  In vitro 
unfolding/refolding experiments of different proteins confirmed the general validity 
of the paradigm and led to the assumption that spontaneous self-assembly also 
happens inside the cell. A first caveat to this assumption was added in the 1980s 
when it was observed that new synthetized polypeptide chains bind transiently to a 
preexisting protein before they fold (Barraclough et al., 1980; Haas, 1983). Later it 
became clear that, in the cell, a large numbers of newly synthetized proteins requires 
the assistance of helper proteins that prevent aggregation and assist folding in vivo. 
In fact, cellular conditions of high protein concentration, temperature and ionic 
strength, are greatly different from the artificial environment of the test-tube, and 
may often favour protein aggregation over correct folding. A large group of 
unrelated protein families, named collectively “molecular chaperones, carry out 
several tasks: assisting a successful folding, signal transduction, assembling, 
targeting, transporting and degradating proteins within the cell [1.2 -1.8] (Figure 
1.1). Their activities increase the yield of protein-folding reactions and aid recovery 
from cellular stress. In some particular conditions, they can also promote protein 
unfolding. 
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In addition to molecular chaperones, cells have evolved two mechanisms for the 
degradation of misfolded proteins, the ubiquitin-proteasome pathway and 
lysosome-mediated autophagy. Under certain conditions, when chaperones cannot 
repair misfolded proteins, chaperone-mediated targeting to the ubiquitin– 
proteasome system or to lysosomes results in selective degradation [1.2 – 1.5]. 
 
Figure 1.1 Scheme of cellular processes regulated by molecular chaperones. Besides 
facilitating protein folding and preventing protein aggregation, the molecular chaperones 
regulate several other cellular processes, such as autophagy, vesicle fusion, signal 
transduction, apoptosis and proteasomal degradation. Abbreviation/acronyms: AIF, 
apoptosis-inducing factor; ER, endoplasmic reticulum; ERAD, endoplasmic reticulum-
associated degradation; HSF1, heat shock transcription factor 1; HSP, heat shock protein; 
LAMP, lysosomal-associated membrane protein; ROS, reactive oxygen species. 
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1.1.1 Heat Shock Proteins 
Conditions of stress, including (but not limited to) temperature elevation, activate a 
cellular programme known as the heat shock response. It is characterized by a 
robust increase in the synthesis of some proteins that are crucial for recovery from 
stress-induced damages. These proteins, named “heat shock proteins” (Hsps), 
contribute to guarantee cell proteostasis by avoiding protein misfolding and 
aggregation. Further, they are involved in protein degradation and disaggregation 
of toxic aggregates by clearance mechanisms. As proteins, chaperones can be 
affected by mutations. The growing number of diseases found to be linked to 
chaperone mutations (see chapter 2), testifies the importance of their role in the 
cellular protein-quality control mechanism.  
Almost all Hsps function as molecular chaperones, and they have been classified 
into six main families on the basis of their approximate molecular mass (in kDa): 
Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and the smallest Hsps (sHsps) with weigh 
less than 40 kDa (See Paragraph 1.1.2). The main features of different members of 
Hsps family are briefly described in the following. 
Hsp100 
Heat shock protein 100 (Hsp100) chaperones are members of the AAA+ protein 
family (adenosine triphosphatases with diverse activities). They share a common 
ATPase domain and form large ring-shaped structures. In yeast, Hsp104, the best-
characterized Hsp100, regulates protein aggregation, disaggregation and 
thermotolerance, but no mammalian homologue has been identified so far [1.9, 
1.10]. 
 
Hsp90 
Hsp90 chaperones are an essential component of the eukaryotic cytosol, where they 
stabilize misfolded proteins and regulate the activity of various signaling proteins, 
including steroid hormone receptors, tyrosine kinases, nitric oxide synthase and 
calcineurin [1.11, 1.12]. 
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Hsp60 
Hsp60 chaperones are heptameric complexes of identical subunits stacked back to 
back in a double-ring structure that contains a large central cavity in which protein 
folding is thought to occur. In eukaryotes, Hsp60 family members (also called 
Group I chaperonins) are found in the mitochondria, and cooperate with a cofactor 
of the Hsp10 family. A second class of chaperonins (Group II chaperonins) is found 
in the eukaryotic cytosol but has no Hsp10 cofactor. The best-characterized Group 
II chaperonin is TRiC, which comprises eight subunits per ring encoded by different 
genes. TRiC is thought to be crucial for the folding of actin and tubulin in the 
eukaryotic cytosol (we will focus on it in the next paragraph) [1.13]. 
 
Hsp70 
Hsp70 chaperones (with Hsp40s, their co-chaperones) assist in the stabilization and 
folding of many substrates and are found in most cellular compartments. In humans, 
11 genes that encode Hsp70 family members have been identified, including the 
constitutive cytosolic member heat shock cognate 70 (HSC70), the stress-induced 
cytosolic Hsp70, the endoplasmic reticulum-localized glucose-regulated protein 78 
(GRP78) and the mitochondrial GRP75 (REF. 104). All Hsp70 proteins have a 
conserved amino-terminal ATPase domain that binds and hydrolyses ATP, and a 
carboxy (C) - terminal substrate-binding domain [1.14]. 
 
Hsp40 
Hsp40 co-chaperones bind Hsp70 through a conserved J-domain and stimulate ATP 
hydrolysis, resulting in a conformational switch that closes the substrate-binding 
pocket of Hsp70 and facilitates the capture of non-native protein substrates. Hsp40s 
also bind protein substrates and target these substrates to Hsp70, enhancing the 
efficiency of the Hsp70/Hsp40 refolding cycle. Higher eukaryotes have many 
Hsp40 family members, whose differential expression or localization might 
regulate the substrate specificity of conserved Hsp70 family members [1.15–1-17]. 
 
Small heat shock proteins 
sHsps have a molecular mass of less than 40 kDa and assemble into large, 
oligomeric structures that resemble a hollow ball. All sHsps contain a conserved, 
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C-terminal α-crystallin domain of about 100 residues that mediates oligomeric 
assembly. Similar to Hsp90 chaperones, sHsps transiently interact with and 
stabilize misfolded substrates, conceivably until the Hsp70/Hsp40 system can 
actively refold them [1.18]. 
 
1.1.2 Group I and group II chaperonines (Cpns) 
The term chaperonin has been often used interchangeably with heat shock protein 
60 (hsp60). In fact, the chaperonins (Cpns) are a ubiquitous family of sequence-
related molecular chaperones, comprising oligomeric proteins of approximately 60 
kDa subunit mass that are essential for protein folding either under normal or 
stressful conditions [1.19-1.21]. 
The Cpns are large, hollow, ATP-dependent nanomachines that promote correct 
folding of a wide range of proteins.  They are involved in the ATP dependent 
folding and refolding of a wide variety of structurally unrelated proteins [1.22] and 
are essential for cell viability at all temperatures [1.23]. 
The Cpns are divided into 2 subgroups: group I and group II. Members of the GroEL 
family (or group I Cpns, Fig. 1.4) are found in eubacteria, mitochondria, and 
chloroplasts. The group II or TRiC (TCP-1 ring complex, see Fig. 1.7) protein 
family is found in the eukaryotic cytosol and in archaebacteria (reviewed by 
Gutsche et al 1999). Of the group II members, only the archaebacterial Cpns are 
heat shock inducible [1.24]. 
 Although the two subfamilies have a similar cage-like structure, there are some 
important differences in the regions that bind substrate proteins (see Fig. 1.9). 
GroEL works with its co-protein GroES and uses an ATPase cycle to transiently 
create an enclosed, enlarged cavity in which protein folding takes place. No co-
protein has been identified for the TCP1 subfamily, but an extra structural element 
built into the apical domain of TCP1 (see Fig. 1.8) may fulfil a similar role to GroES 
[1.25, 1.26]. GroEL (hsp60, cpn60) is a 14-mer of 58 kDa subunits in two rings, 
and its co-protein GroES (hsp10, cpn10) is a heptameric ring of 10 kDa subunits. 
The related eukaryotic cytosolic chaperonin, CCT (TCP1, TRiC), contains two 
rings of eight subunits, derived from eight related, but distinct, gene products [1.27]. 
In the archaebacteria, the thermosome, or TF55, has two rings of eight or nine 
subunits, each composed of one or two subunit types [1.28]. The human CCT 
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(chaperonin containing TCP1) is a complex assembly of eight similar but non-
identical [1.29-1.31] subunits which functions to fold non-native proteins through 
the alternative opening and closing of the two chambers. By contrast, many 
hyperthermophilic Archaea, including Pyrococcus furiosus and several groups such 
as Pyrodictium, Methanopyrus, and Pyrobaculum spp have a single group II Cpn 
subunit. The double ring of these archaea is therefore composed of 16 identical 
subunits and is minimally complex. Hyperthermophile Cpns are exceptionally 
stable in vitro [1.32, 1.33], affording a suitable model for studying oligomerization 
of group II Cpns such as the human CCT complex (see chapter 4, 4.3).  
 
1.1.3 Working Mechanism of molecular chaperones 
 
Although playing similar jobs, the structures and modes of action of the molecular 
chaperone families are remarkably diverse. Some families are very specific in their 
action, whereas others are very general. Some, but not all, use the binding and 
hydrolysis of ATP to control the release and binding of substrate proteins. Based 
on their mechanism of action, molecular chaperones have been divided into three 
functional subclasses [1.8]: 
- Folding chaperones (e.g., DnaK and GroEL in prokaryotes, and Hsp60 and 
Hsp70 as well as the HspB group of Hsps including Hsp27 and HspB1 in 
eukaryotes) rely on adenosine triphosphate (ATP)-dependent 
conformational changes to mediate the net refolding/unfolding of their 
substrates. 
- Holding chaperones (e.g. Hsp33 and Hsp31) bind partially folded proteins 
and maintain their substrates on their surface to await availability of folding 
chaperones. 
- Disaggregating chaperones (e.g. ClpB in prokaryotes and Hsp104 in 
eukaryotes), which promote the solubilization of proteins that have become 
aggregated as a result of stress 
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1.1.4 Modes of substrate binding 
Though few models of modes of substrate binding of the Hsps are available, the 
detailed information obtained so far are strongly interesting. The diversity of 
chaperone-polypeptide interactions is illustrated schematically in Figure 1.2. 
 The small Heat Shock Protein (sHsps) have an enormous capacity for substrate 
binding, but the structural basis of their binding remains unknown. Denatured 
proteins could bind sHsps by coating their surface, or perhaps could be encased 
inside a shell formed by the sHsp subunits. The latter possibility would require 
disassembly and reassembly of the sHsp oligomers. This sHsp class is not known 
to have ATPase activity and seems to act as a passive binder of non-native protein 
in response to cellular stress [1.34, 1.35]. 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
DnaK (Hsp70, BiP) is the Escherichia coli homologue of a large and important class 
of Hsps present in the cytosol, endoplasmic reticulum, mitochondria and 
chloroplasts [1.36]. It acts in concert with co-proteins DnaJ (involved in substrate 
binding and presentation) and GrpE (a nucleotide-exchange factor). Crystal 
structures of both the ATPase domain, which is structurally related to actin and 
hexokinase [1.37], and the substrate-binding domain [1.38] are separately known. 
The latter shows a remarkable brick-shaped domain permeated by a hole through 
Figure 1.2 Schematic representation of the possible modes of substrate binding in Hsps 
(Hsp25, Hsp70 and Hsp60). Nonnative polypeptide is shown in pink and the various 
chaperone architectures in grey. For hsp25, the location of substrate binding is unknown. 
The substrate could be enclosed in a shell of protein subunits rather than coating the outside, 
as shown here. 
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which the bound peptide runs. A α-helix running across the top of this hole is 
proposed to serve as a hinged lid, allowing entry and exit of the polypeptide-chain 
segment that binds in a completely extended conformation. ATP binding and 
hydrolysis control release and binding of the substrate by an unknown mechanism 
involving interactions between the two domains and DnaJ. 
In contrast with the previous two examples, hsp60 (GroEL, cpn60) forms a large 
cage-like structure with two rings of seven subunits, each surrounding a central 
cavity.  
The protein-folding intermediate binds to hydrophobic sites lining these cavities. 
The hsp100 family has a hexameric ring structure [1.39, 1.40] and it seems plausible 
that the unfolded substrate might also bind in the central cavity in this case. Some 
of these ATPases associate with multi-subunit proteases and play a role in protein 
degradation, as well as in thermos-tolerance. They have the capacity to dissociate 
protein aggregates; expression of yeast hsp104 at normal levels is required for 
conversion and maintenance of the psi+ phenotype, a prion-like phenomenon 
involving the aggregation of the translation termination factor sup35 [1.41]. Hsp90 
interacts with a range of steroid receptors and kinases by an as-yet-undetermined 
mechanism. The recent crystal structure of the N-terminal domain has revealed an 
ATP-binding site and an unexpected similarity to the fold of DNA gyrase [1.42]. 
The endoplasmic reticulum proteins calnexin and calreticulin are chaperones that 
act more specifically by binding to given oligosaccharides and performing quality 
control during the processing of glycoproteins [1.43]. Peptidylprolyl isomerase 
(PPI) and protein disulphide-isomerase (PDI) catalyse the cis-trans isomerization 
of proline residues and the isomerization of disulphide bonds, respectively. These 
are potentially rate-limiting steps in the folding process and several examples are 
now known in which their activities are required for successful protein folding 
[1.44, 1.45]. 
Finally, the pro-sequences of certain proteins act as intramolecular chaperones, 
facilitating the acquisition of the native state before being removed by processing 
to yield the active protein [1.46]. It should be noted that this is a case of specific 
catalysis of a folding step, as presumably the pro-sequence has evolved to stabilize 
the transition state in the folding reaction of the main protein chain. This is very 
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different from the concept of a general molecular chaperone, where stabilization of 
transition states is implausible for a wide range of substrates with different folds. 
 
1.1.5 General principle of molecular chaperones in preventing 
aggregation 
 
As stated above, one of the common features of the molecular chaperone family is 
an interaction with non-native proteins, but how can this basic affinity be translated 
into an increase in the efficiency of a typical folding reaction (see Scheme Fig. 1.3). 
If the intermediates of a protein-folding reaction are sequestered by the addition of 
a molecular chaperone, this passive binding event alone can improve the yield of 
that folding reaction as long as two criteria are met: first, that the stability of the 
interaction between chaperone and folding intermediate is not greater than the free 
energy of folding, and secondly, that the loss of yield in the folding reaction is due 
to aggregation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If the rate of a multimolecular aggregation process (va) is more dependent on the 
concentration of intermediate [I] than the rate of productive unimolecular protein 
folding (vf), the yield of folding is increased by the reversible formation of a 
chaperone-intermediate (C-I) complex that lowers the concentration of folding 
Figure 1.3 Folding pathway of a typical oligomeric enzyme. Unfolded polypeptide 
chains (U) undergo a rapid hydrophobic collapse to form a compact folding intermediate 
(I). This folding intermediate folds productively (with a rate vf) to form a folded, native-
like monomer (F), which then dimerizes to give the native active enzyme complex (D). 
However, losses in the productive folding reaction arise from non-specific association 
(with rate va) of I to form aggregates (Agg). In the presence of a molecular chaperone (C), 
a third possible fate for the folding intermediate exists: it can form a complex with the 
molecular chaperone (C:I) with an affinity defined by the dissociation constant (Kd) for 
this interaction. 
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intermediate in solution, i.e. if vf=kf[I] and va=ka[I]n, then a, the partition coefficient 
between folding and aggregation, is given by: 
 
If the value of [I] is high, then α→0 and aggregation is favoured. Conversely, if [I] 
is low, then α→1 and folding is favoured. Implicit in this analysis, however, is the 
fact that there must be a concomitant decrease in the observed rate of folding 
because of this drop in folding intermediate concentration [1.47]. If an equilibrium 
between bound and free states exists, then under conditions of heat shock or other 
cellular stress the amount of denatured protein will increase and the equilibrium 
will be shifted towards the bound state. Thus proteins would be stabilized by 
molecular chaperones in these conditions. When conditions improve, any non-
native proteins that are released will have a better chance of reaching the native 
state, and the equilibrium will shift toward the free state. 
Chaperones also deliver proteins to proteolytic complexes [1.48], presumably a 
mechanism for disposing of damaged proteins that cannot reach the native state, or 
proteins that have been targeted for proteolysis as part of programmed turnover or 
cell death. 
 
 
1.2 GroEL/HSP60 oligomeric structure and allosteric states 
 
The best know molecular chaperone is Escherichia coli GroEL. It is formed by two 
back-to-back stacked rings of seven subunits that alternately serve as containers for 
the folding of other proteins subunits. The structures of the GroEL oligomer and its 
various complexes have been determined by X-ray crystallography [1.49, 1.50] and 
by electron cryo-microscopy [1.51]. Figure 1.4 shows the crystallographic structure 
of both the oligomer and a single subunit. The oligomer is cylindrical and formed 
from two heptameric rings stacked back-to-back. Each ring encloses a central cavity 
and there are holes in the sides of the structure. The interface between the two rings 
is flat, except for the two contacts (numbered 1 and 2) formed by the base of each 
subunit with its neighbours in the opposite ring. On the right is shown the backbone 
structure of the outlined subunit with the three domains colour-coded. The termini 
are located close together in the equatorial domain (blue), which forms the inter-
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ring and most of the intra-ring contacts. The inter-ring contacts are formed by salt 
bridges, labelled C1 and C2. This domain also contains the nucleotide-binding site, 
and an adenosine 5’-[γ-thio-triphosphate (ATP[S]) molecule is shown bound in the 
site [1.50]. An exposed region of anti-parallel chains connects the equatorial 
domain to the intermediate domain. This connecting region is a site of hinge 
rotation, labelled hinge 1. At the top of the intermediate domain, another hinge 
region (hinge 2) connects to the apical domain, which contains the binding sites for 
polypeptide substrates and for GroES [1.52]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Structure of the GroEL oligomer and subunit: Shown on the left is the crystal 
structure of GroEL filtered to 2.5 nm resolution, showing the double-ring structure and the 
location of an individual subunit within the oligomer. Shown on the right is the backbone 
trace of the GroEL subunit as described in the text.  
 
 
Together with ATP and a co-protein GroES, it constitutes a molecular machine that 
binds non-native polypeptides and facilitates their refolding in an ATP-dependent 
manner (Fig. 1.5). The action of the ATPase cycle causes the substrate-binding 
surface of GroEL to alternate in character between hydrophobic 
(binding/unfolding) and hydrophilic (release/folding). ATP binding initiates a 
series of dramatic conformational changes that bury the substrate-binding sites, 
lowering the aﬃnity for non-native polypeptide [1.7]. 
 
 
Hinge 2     
Hinge 1     
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1.3 TRiC: The protein folding machine in Eukaryotes 
 
An interesting variant of the GroEL structure is seen in the CCT subfamily, 
exemplified by the archaebacterial thermosome. This chaperonin has two rings of 
eight subunits each, and rather low sequence homology with GroEL. The only 
detectable homology is in the equatorial domain, particularly around the ATP-
binding site, whereas the apical domain appears to be quite divergent [1.53]. 
However, the crystal structure of the apical domain reveals that, despite the lack of 
sequence homology, it has a similar overall fold except for one unique and 
prominent feature (Figure 1.6) [1.54]. In the region that forms the hydrophobic 
binding site in GroEL, the thermosome apical domain has a long extension, which 
forms a α-helical protrusion. This extension is highly conserved in the TCP1 family 
and contains hydrophobic residues proposed to act as substrate-binding sites. The 
extensions would arch over the central channel to form a substrate-binding surface 
very different from that in GroE chaperonins [1.54]. In fact, the formation of a 
Figure 1.5 GroEL functions as chaperone by collaborating with GroES. (1) Non-
native protein binds to the trans ring of a GroEL-GroES complex. End-to-end exchange of 
GroES (possibly through a symmetric complex with a GroES molecule bound to each of 
the GroEL rings) results in the encapsulation of the protein substrate in the cis cavity. (2) 
In the presence of ATP, productive folding of protein substrates can occur in the cis cavity. 
(3) Release of GroES and substrate protein (whether folded or not) results in the 
regeneration of the acceptor complex for non-native protein.  
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closed lid has been observed in the recently determined crystal structure of the intact 
thermosome hexadecamer [1.55]. This difference is consistent with the observed 
differences in specificity of TCP1 and GroE chaperonins, for example, in the 
folding of luciferase. Figure 1.6 shows an overlay of the GroEL and thermosome 
apical domain folds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRiC (T-complex protein-1 ring complex, also known as CCT) is an essential 1 
MDa eukaryotic chaperonin. It has a double-ring structure with a central cavity in 
each ring [1.56]; each ring is composed of eight homologous but distinct subunits 
(CCT 1–8) [1.57, 1.58], arranged in a speciﬁc order [1.59, 1.60] (Figure 1.7A). 
Each subunit is ~60 kDa and consists of three domains—apical, intermediate, and 
equatorial (Figure 1.7B). While the sequence of the equatorial and intermediate 
domains is conserved, that of the apical domains is highly diverged among the eight 
subunits [1.61]. Multiple structures have been reported for TRiC [1.62- 1.64] using 
x-ray crystallography (Figure 1.7A) and single particle cryo-EM.  
 
 
 
 
 
Figure 1.6 Backbone alignment of the thermosome and GroEL apical domains. The 
thermosome (gold) and GroEL (blue) apical domains are aligned, highlighting the helical 
extension present in the thermosome. The fold homology is clear in the β-sheet core of the 
domain. The structures were aligned by selecting equivalent residues in the conserved β-
strands and performing a rigid body fit with Quanta (Molecular Simulations). The Figure 
was produced with GRASP [1.55]. 
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TRiC assists productive folding of substrate proteins by undergoing conformational 
changes that are ATP-dependent [1.65-1.68]. The structures of the TRiC in the 
presence of varied nucleotide conditions have been solved using cryo-EM at 
intermediate resolution, which have led to an improved understanding of the large 
conformational changes that occur upon nucleotide binding and hydrolysis [1.69, 
1.70]. The conformational cycling begins with the binding of ATP and a transition 
of the complex to the closed conformation required for ATP hydrolysis to bring the 
lid helices into close proximity. Opening of the lid occurs in conjunction with 
releasing ADP from the active site. The complex can exist in an asymmetrical 
conformation with one ring closed and one open even during ATP cycling 
conditions, suggesting an inter-ring allosteric model mediated through a two-stroke 
mechanism (see Fig. 1.8) [1.71]. However, the allosteric communication that occurs 
between the rings is not well understood. 
Although the mechanisms of TRiC-substrate recognition, binding, and folding still 
remain under investigation, it is known that each of the subunits can recognize 
different polar and hydrophobic motifs within substrate proteins [1.72]. TRiC 
Figure 1. 7 Molecular architecture of TRiC/CCT. (A) The end-on and side views of the 
X-ray crystal structure of TRiC, modified from PDB ID 2XSM, show that TRiC is a 
double-ringed structure composed of eight homologous but distinct subunits (CCT1–8). 
Each subunit is shown having a different color with the specific subunit order indicated. 
The black arrowhead indicates CCT1, which has unique asymmetrical features; (B) The X-
ray structure of CCT1 is shown as a representative subunit. Helix-11 (H11), the putative 
substrate recognition site is indicated by the arrow. 
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interacts with approximately 10% of the proteome and its function is absolutely 
essential for viability [1.73]. TRiC substrates have been identiﬁed by multiple 
groups [1.74, 1.75] and, recently, Yam and colleagues determined ~200 cellular 
TRiC substrates using proteomic global approaches based on immunoprecipitation 
and mass spectroscopy [1.73]. From the secondary structure analysis of the 
substrates, TRiC has been shown to mediate the folding of a number of -sheet rich 
proteins, including telomerase cofactor TCAB1 [1.76], the cell cycle regulators 
CDC20 and CDH1, as well as members of the STAT family of transcription factors 
[1.77 ].  
However, the full repertoire of TRiC substrates remains underdetermined, in part, 
because specific motifs characteristic of TRiC substrates have not been identified. 
As a general principle, TRiC substrates have a higher potential to aggregate. 
Substrate proteins also are often large, have extended hydrophobic stretches, or are 
involved in multi-protein complexes [1.78]. The ability to assist such a wide range 
of proteins with diverse folds and sequence properties raises the potential for 
multiple mechanisms through which TRiC can recognize substrates and promote 
their folding.  
Recent in vitro work has illuminated the molecular determinants of substrate 
interaction with the apical domains of TRiC subunits. Using known subunit-
substrate pairs, Joachimiak and colleagues have demonstrated that substrate motifs 
are recognized by a cleft formed between Helix 11 (H11) and a proximal loop in 
the TRiC apical domains (Figure 1.7B). In addition, the subunit arrangement 
recently has been identiﬁed with a combinatorial approach that employed X-ray 
crystallography and chemical crosslinking mass spectrometry as well as 
bioinformatics [1.79] (Fig. 1.7A). The subunit arrangement of TRiC leads to the 
spatial partitioning of subunits with different chemical properties. Speciﬁcally, 
subunits are segregated by their ATP-binding afﬁnities (High afﬁnity subunit: 
CCT1,2,4,5, Low afﬁnity subunit: CCT3,6,7,8) [1.80]. Thus, the hetero-oligomeric 
nature of TRiC generates chemically asymmetric features, which likely provide the 
basis for the unique ability of TRiC to fold speciﬁc substrates [1.81]. The meaning 
of this asymmetric nucleotide usage and allosteric mechanism in the context of 
protein folding remains an area of ongoing research [1.82]. 
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Figure 1.8 Cryo-EM study of TRiC conformational cycle. Cartoon diagram illustrates 
the TRiC conformational transitions in the apo state and four distinct nucleotide 
biochemical states throughout the ATPase cycle. In addition, a representative 
micrograph of ice-embedded TRiC in each state is shown. Scale bar is 320 A. 
Figure 1.9 Model of the Models for the chaperone-assisted folding of newly synthesized 
polypeptides in the cytosol. (A) Eubacteria. TF, trigger factor; N, native protein. Nascent chains 
probably interact generally with TF, and most small proteins (65 to 80% of total) fold rapidly 
upon synthesis without further assistance. Longer chains (10 to 20% of total) interact 
subsequently with DnaK and DnaJ and fold upon one or several cycles of ATP-dependent binding 
and release. About 10 to 15% of chains transit the chaperonin system – GroEL and GroES – for 
folding. GroEL does not bind to nascent chains and is thus likely to receive an appreciable fraction 
of its substrates after their interaction with DnaK. (B) Archaea. PFD, prefoldin; NAC, nascent 
chainassociated complex. Only some archaeal species contain DnaK/DnaJ. The existence of a 
ribosome-bound NAC homolog, as well as the interaction of PFD with nascent chains, has not 
yet been conrmed experimentally. (C) Eukarya – the example of the mammalian cytosol. Like 
TF, NAC probably interacts generally with nascent chains. The majority of small chains may fold 
upon ribosome release without further assistance. About 15 to 20% of chains reach their native 
states in a reaction assisted by Hsp70 and Hsp40, and a fraction of these must be transferred to 
Hsp90 for folding. About 10% of chains are co- or post translationally passed on to the chaperonin 
TRiC in a reaction mediated by PFD. Image and caption taken from Hartl and Hayer-Hartl (2002). 
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1.4 Chaperonins as nanocarries for intracellular drug delivery 
 
The realization of ‘surgical nanomachines’ (which detect particular biological 
signals and accordingly evaluate which tasks are required to cure wounded tissues), 
envisaged by Feynman, is undoubtedly an ultimate scientific challenge. However, 
at present, there is still a long way to go before we are able to synthesize such 
intelligent, tailored nanomachines [1.83, 1.84]. 
 Biomolecular machines are elegant nanoscale devices formed by the elaborate 
assembly of protein subunits, and play crucial roles in a range of biological events 
including cell division, intra/intercellular transportations, cellular movements and 
signal transductions [1.85 1.86]. In biological systems, these machines operate 
using a mechanical force, generated by conformational changes of constituent 
protein subunits, and chemically fuelled by adenosine-5′-triphosphate (ATP) and 
its analogues. The chemomechanical forces generated are tiny (5–60 pN) [1.87], 
but can cleave non-covalent interactions that form at nanoscale biointerfaces. We 
therefore envisioned that it might be possible to assemble an intelligent nanocarrier 
based on proteins, and tailor it to break up to release drugs in ATP-rich domains, 
under chemomechanical forces similar to those that occur in biological systems. 
Endogenous ATP, produced during inflammation [1.88], is considered an essential 
immunogenic signalling molecule. Although various stimuli-responsive synthetic 
carriers have already been reported [1.89-1.92], ATP-fuelled nanocarriers 
composed of integrated biomolecular machines are quite attractive, because it is 
possible to take full advantage of their sophisticated stimuli-specific operations.  
Recently has been reported ([1.83]) a prototype of such intelligent nanocarriers, 
nanotubes assembled by supramolecular polymerization of a chaperonin GroEL 
mutant that has an extra-large molecular mass of ~800 kDa ([1.93]; Fig. 1.10). In 
biological systems, GroEL captures denatured proteins into its cavity and promotes 
their refolding. To release guest proteins after refolding, GroEL undergoes 
conformational changes induced by the hydrolysis of ATP into ADP that lead to the 
opening and closing of its cavity [1.93].  In the same work [1.83], was demonstrated 
how this nanotubular carrier (NT, Fig. 1.10a) indeed also breaks up into short-chain 
oligomers according to the expected mechanism, triggered by ATP. They also 
found that BANT (a surface-modified version of the nanotube with a boronic acid 
(BA) derivative; Fig. 1.10b) can enter into human epithelial carcinoma (HeLa) cells 
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and respond to intracellular ATP. Finally, it was shown that this nanocarrier 
possibly provides a general strategy for intracellular delivery of drugs, when these 
are suitably anchored onto an irreversibly denatured guest protein such as α-
actalbumin (α -LAdenat) through an enzymatically cleavable linker (Fig. 1.10c). 
This scission occurs with a sigmoidal dependence on ATP concentration, which 
means that the nanocarrier can differentiate biological environments in terms of the 
concentration of ATP for selective guest release. Furthermore, biodistribution tests 
reveal preferential accumulation of the nanocarriers in a tumour tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Schematics of the basic strategy for ATP-responsive intracellular drug 
delivery. a, Schematics of the preparation from mutant GroELCys and Mg2+-mediated 
supramolecular polymerization of GroELMC, forming a nanotube (NT), and its scission by 
ATP-fuelled chemomechanical conformational changes of the GroELMC building units. In 
the nanotube, the GroELMC monomer units are tightly connected together at their apical 
domains through multiple MC–Mg2+–MC bridges (MC, merocyanine). However, a 
mechanical force, generated by the ATP-fuelled conformational changes, is large enough 
for this multivalent GroELMC connection to break. b, Schematic illustration of the 
preparation of cell-penetrable BANT by modification of the surface amine moieties of the 
nanotube with a 2-(hydroxymethyl)phenylboronic acid cyclic monoester derivative (BA). 
c, Schematic illustration of the basic strategy of ATP-responsive intracellular drug delivery 
with cell-penetrable BANT, using as the guest irreversibly denatured α -lactalbumin (α-
DrugLAdenat) appended with drugs through an enzymatically cleavable ester linker (BANTƆ  
α-DrugLAdenat). Chemomechanical scission of BANT Ɔ α-DrugLAdenat, triggered by binding 
with intracellular ATP, results in admission of esterase into the open cavity of chain-broken 
GroELMC Ɔ α-DrugLAdenat, thereby allowing for ester-bond cleavage and subsequent release 
of drugs. 
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1.5 Chaperone-like systems: Caseins 
 
The caseins are a heterogeneous group of dairy proteins constituting 80% of the 
protein content of bovine milk. The operational definition of casein is that 
proportion of total milk protein which precipitates on acidification of milk to a pH 
value of 4.6 [1.94-96]. The remaining dairy proteins, known collectively as whey 
proteins, do not precipitate. Caseins are synthesized in the mammary gland and are 
found nowhere else among the plant and animal kingdoms [1.97]. The casein family 
of proteins comprises α, β- and k-caseins, all with little sequence homology [1.98]. 
As their primary function is nutritional, binding large amounts of calcium, zinc and 
other biologically important metals, amino acid substitutions or deletions have little 
impact on function. The caseins also lack well-defined structure and as a result their 
amino acid sequence is less critical to function than in many ‘classic’ globular 
proteins. Hence, the caseins are one of the most evolutionarily divergent protein 
families characterized in mammals. Alpha-casein, αS-casein, is in fact two distinct 
gene products, αS1 - and αS2 -casein, with the ‘S’ denoting a sensitivity to calcium. 
Of all the caseins, αS1- and β-casein are predominant in bovine milk, representing 
37 and 35% of whole casein respectively, whereas αS2- and k-casein make up 10 
and 12% of whole casein, respectively [1.97].   
The casein proteins and their derivatives have been used by the food industry as 
important nutritional and stabilising proteins for many years [1.99]. Early studies 
showed that whole casein (i.e. αS-, β- and k-casein) prevented heat induced 
aggregation of whey proteins, even in calcium-containing systems [1.100 - 1.103]. 
It was proposed that the stabilizing action of the caseins on heat-denatured target 
proteins occur through non-specific interactions. This opened up a new avenue of 
uses for casein proteins in stabilizing both milk and non-milk proteins and thereby 
contributing to novel properties of milk products. It was then demonstrated in 1999 
that individual αS-casein possessed molecular chaperone activity [1.104]. Since 
then, β- and k-casein have both been shown to also act as molecular chaperones 
[1.105, 1.106. 1.107]. The presence of high numbers of phosphate groups in the 
casein proteins appears to be important for chaperone action against amorphously 
aggregating target proteins under both reduction and heat stress, with studies 
showing that removal of these in αS- and β-casein reduced their ability to prevent 
the aggregation of target proteins [1.108, 1.109]. 
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1.5.1 Structural features of Caseins 
 
Structurally, the caseins are classified as ‘intrinsically or natively disordered’ 
proteins under physiological conditions [1.110. 1.111.105, 1.106]. This disordered 
structure, which is present to some extent even in globular proteins, is different to 
random coil conformation. In natively disordered proteins, conformations of these 
regions are still relatively fixed with respect to the  and angles of the peptide 
bonds, as opposed to true ‘random coil’ polypeptide chains, which exhibit greater 
and more rapid fluctuation in bond angles [1.99]. The lack of well-defined structure 
in the casein proteins is believed to facilitate proteolysis and therefore ready 
absorption of amino acids and small peptides in the gut [1.97], but is another likely 
factor in the unwillingness of the caseins to crystallise to provide a 3D crystal 
structure [1.112]. Physical characterisations of caseins in solution and predicted 3D 
models have shown that the caseins have relatively little tertiary structure, but 
possess some secondary structure, similar to the classic ‘molten globule’ states 
described in [1.113]. The greatest degree of secondary structure exists in αS2- and 
k-casein, mainly in the form of β-sheets and β-turns rather than α-helix [1.114-
1.116].  
The formation of higher proportions of secondary and tertiary structural elements 
in the caseins is likely to be inhibited by high numbers of proline residues which 
distort protein folding into α-helices and β-sheets [1.97].  Each of the casein 
proteins has a high degree of hydrophobicity as a result of containing approximately 
35-45% non-polar amino acids (e.g. Val, Leu, Phe, Tyr, Pro). However, this does 
not preclude them from being quite soluble in aqueous solvents due to the presence 
of high numbers of phosphate and sulfur-containing amino acids, and in the case of 
k-caseins, carbohydrates [1.97]. The flexible and relatively unfolded structure 
likely favors the exposure of the hydrophobic regions that tends to occur in patches 
along the sequence of the caseins, interspersed with hydrophilic regions. It is this 
structural feature that is credited with making the caseins good emulsifying agents, 
a property exploited in the food industry. The clustered exposed hydrophobicity is 
also thought to be a major feature of the molecular chaperone action of the caseins 
[1.102] as discussed in the following.   
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1.5.2 Alpha-Casein as a Molecular chaperone 
 
Investigations into the chaperone action of a αS-casein have revealed that it 
prevented the stress-induced aggregation of natural target proteins such as the whey 
proteins β-lactoglobulin and bovine serum albumin, but also of unrelated proteins 
such as alcohol dehydrogenase and carbonic anhydrase.  The stabilization of 
partially unfolded ‘target’ proteins takes place through direct interactions resulting 
in the formation of   soluble, high molecular weight complexes similar to those 
induced by small heat-shock proteins (sHsps) and another unrelated chaperone, 
clusterin. In addition, it has been shown that αS-casein is able to protect target 
proteins from aggregation in fibrillar aggregates, and that its chaperone activity is 
dependent on the target protein present, S the stress conditions applied, the mode 
of protein aggregation (i.e. amorphous versus fibrillar), the speed of aggregation, 
and the presence of competing ions. 
Previous work showed that αS-casein, acting as a molecular chaperone under these 
conditions, was able to interact with partially unfolded target proteins and prevent 
their incorporation into insoluble aggregates which would then have formed 
precipitates [1.104]. As shown in Figure 1.11, the putative mode of action of αS-
casein is based on a similar model proposed for sHsps where a natively folded 
protein (N) unfolds via a number of intermediately folded states (I1, I2 etc.) or 
‘molten globule’ states on its way to the unfolded state (U).  
 
 
 
 
 
 
 
 
 
 
  
Figure 1.11 Putative mechanism of action of αS-casein: showing its interaction with 
target proteins on the folding and off-folding pathways. See text for explanation. Reprinted 
with permission from [1.117].   
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This folding and unfolding is fast and reversible and involves the exposure of 
hydrophobic regions normally buried in the interior of the protein.   
Under conditions of cellular stress, when intermediately folded states are present 
for longer periods, self-association is promoted by the prolonged exposure of 
hydrophobic surfaces. When self-association occurs, the intermediately folded 
states enter the off folding pathways which are slow and irreversible and may lead 
to either amorphous aggregation as shown on the right hand side of the figure 1.11 
or to fibril formation as shown on the left. Amorphous aggregates result from 
disordered aggregation and lead to the formation of insoluble protein precipitates. 
Conversely, the ordered amyloid pathway leads to highly ordered β-sheet stacking 
giving cross β-sheet fibrils. Casein micelles or oligomeric forms of αS-or β-casein 
are able to interact with partially folded proteins and stabilize them against 
aggregation and precipitation by forming a soluble high molecular weight (HMW) 
complex [1.117]. 
Understanding the mechanism/s by which αS-casein exerts the role of molecular 
chaperone is of great interest to the dairy industry as it may provide an alternative 
method for long life milk treatment [1.94].   Processing treatments in dairy foods 
have the potential to induce partial or complete protein denaturation. The presence 
of proteins in denatured configuration may either present a problem or offer 
opportunities for novel foods to be developed [1.118]. This is where the action of 
molecular chaperones may play an important role. Thus, a better understanding of 
the aggregation processes in milk and how these can be modified opens up potential 
avenues for new milk based products with novel textures and other organoleptic 
properties to be developed. Moreover, investigation on its interaction mechanism 
could help to better understand the structural basis of the substrate binding in sHsps, 
which is able to exert a stabilizing function through direct interaction (see chapter 
4, 4.2). 
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Chapter II 
“Molecular chaperones involved in human diseases” 
 
2.1 Molecular Chaperones and protein misfolding diseases  
 
Proteins are central to all biological processes. To become functionally active, 
newly synthesized protein chains must fold into unique three-dimensional 
conformations, based on the information encoded in their amino acid sequences. 
Although in vitro many proteins can fold to their native state spontaneously without 
the aid of additional components, in vivo molecular chaperones are essential for 
protein folding to occur with high efﬁciency. As described in chapter 1 the main 
role of these components is to prevent protein misfolding and aggregation, off-
pathway reactions that would otherwise limit the folding yield under cellular 
conditions. 
In recent years, the process of protein folding has been recognized of considerable 
medical relevance. Indeed, a number of human diseases are now known to result, 
directly or indirectly, from aberrant folding reactions. Classic examples include 
Alzheimer’s disease, cystic ﬁbrosis and hypertrophic cardiomyopathy, to mention 
only a few (see Table 2.1).  
 
 
 
 
 
Panchanan Maiti et al., Molecular Chaperone Dysfunction in Neurodegenerative Diseases and Effects of Curcumin BioMed 
Research International Volume 2014, Article ID 495091, 14 pages http://dx.doi.org/10.1155/2014/495091   
Diseases Genes 
involved 
Risk factor Proteins 
involved 
Pathology Affected 
brain areas 
Symptoms 
Alzheimer’s APP and 
presenilin 1, 2 
 ApoE4 A𝛽 and Tau A𝛽-plaque and 
Tau tangle 
Hippocampus 
and frontal 
cortex 
Memory loss, personality 
change, worried, and 
depressed 
Parkinson’s 𝛼-synuclein, 
Parkin, CHL-1, 
and LRRK2 
Tau linkage 𝛼-ynuclein and 
tau 
Lewy body and 
tangle 
Substantia 
nigra,striatum,  
and PFC 
Impairment of 
sensorimotor coordination 
and cognition 
Huntington Huntingtin 
(HTT) 
Number of CAG  
repeats in HTT 
allele 
Huntingtin Inclusion odies 
in cytoplasm 
and nucleus 
Striatum Uncontrolledovements, 
clumsiness, and balance 
impairment 
Prion PRNP Homozygosity at 
 prion codon 129 
PrPSc Prion plaque Whole CNS Memory loss, personality 
change, and movement 
disorder 
Amyotrophic 
Lateral sclerosis 
SOD — SOD1 Bunina body Motor neuron  
of CNS 
Disturbances of 
muscularactivity 
Multiple sclerosis HLA, IL2RA,  
and IL7RA 
Kinesin KIF1B, 
Vit D 
— Demyelinating 
lesion 
White matter of 
the brain and 
spinal cord 
Physical and cognitive 
disability 
Tauopathies Tau Tau-linkage Tau Tau tangle Whole CNS Memory loss 
Lewy bodies 
Dementia 
PARK11 E4 allele of ApoE 𝛼-Synuclein 
and ubiquitin 
Lewy bodies Hippocampus, 
amygdale, and 
frontal cortex 
Impair,alertness/attention 
movement,posture,muscle 
stiffness,emoryloss, 
hallucinations, confusion 
Table 2.1 Examples of human diseases caused by protein misfolding  
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Human misfolding diseases arise when proteins adopt non-native conformations 
that endow them with a tendency to aggregate and form intra- and/or extra-cellular 
deposits. Hence, misfolding diseases result from the failure of proteins to reach their 
active state or from the accumulation of aberrantly folded proteins. 
There are various mechanisms by which the accumulation of misfolded protein 
chains may cause cellular dysfunction, and often a combination of mechanisms 
appears to be responsible for the disease. Misfolded polypeptides not only lose their 
normal function, but may also form toxic species, including oligomers or larger 
aggregates (e.g. amyloid precursor protein (APP) in Alzheimer’s and other 
neurodegenerative diseases). Moreover, they may be prevented from reaching their 
proper cellular localization due to retention and/or degradation (e.g. CFTR in cystic 
ﬁbrosis), or may exert a dominant negative effect by preventing the function of 
interacting partners (e.g. myosin in hypertrophic cardiomyopathy). 
In aggregation diseases, speciﬁc peptides or misfolded proteins, often as a result 
of mutations, can give rise to amyloid-like deposits, i.e. highly ordered ﬁbrillar 
aggregates (Fig. 2.1).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 A scheme depicting common features of misfolding and aggregation in 
neurodegenerative misfolding diseases. The toxic aggregation pathway begins when a 
monomeric disease protein undergoes a structural transition from a native fold into a misfolded 
abnormal conformation. Aggregation proceeds via a multi-step process that involves intermediate 
species, which are thought to be less stable, but more toxic, than the final mature fibrils. These 
species may recruit or interact aberrantly with essential cellular components, including 
machinery of the quality control system. Sequestration of these cellular components may inhibit 
their cellular function, thus contributing to toxicity. Aggregation intermediates may also form 
doughnut-shaped assemblies that interact with membranes to form pores, disrupting cellular 
homeostasis. The end products of the aggregation process accumulate in disease-associated 
deposits, such as amyloid fibrils with cross-β structure. Molecular chaperones Hsp70 and Hsp40 
may prevent the conversion of native protein species into toxic, amyloidogenic intermediates and 
instead facilitate the deposition of disease proteins in non-toxic, disordered aggregates. On the 
right top (panels a and b): Suppression of huntingtin fibril formation by molecular chaperones.  
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In AD, extracellular Aβ peptide deposition is thought to be intimately associated 
with the initiation of disease, whereas in certain forms of PD it is the intracellular 
formation of aggregates of the protein alpha-synuclein [2.1]. HD is caused by a 
mutant version of the protein huntingtin, which results in an expansion of its 
polyglutamine (polyQ) domain and renders the protein aggregation-prone [2.2]. 
The same type of mutation gives rise to a collection of other neurodegenerative 
polyQ diseases, including SCAs and Kennedy’s disease. 
Nuclear inclusions of mutant huntingtin, or other polyQ-containing disease 
proteins, in brain tissue are a key feature of these dominantly inherited disorders. 
The central event in CJD is the extracellular deposition of aggregates of abnormally 
folded prion protein, PrPSc, in the brain and nervous system of affected individuals. 
In each of these cases, it is thought that either the aggregates of the disease protein 
themselves or, more likely, the process of their formation confers cellular toxicity, 
thus supporting the notion that misfolded disease proteins act through a gain-of-
function mechanism that eventually leads to cell death. 
The disease proteins involved in aggregation disorders have no obvious sequence 
similarities, but the amyloid ﬁbrils into which they can convert are very similar in 
morphology. Amyloid ﬁbrils often consist of two to six ‘protoﬁlaments’ which 
share a common core structure based on the presence of highly ordered β-sheets, a 
so-called cross -structure  [2.3]. The ﬁbrillar deposits may be organized into larger 
aggregates or amyloid plaques, which reside outside the cell in the case of AD and 
CJD. In PD and HD, structurally similar amyloid-like deposits are found inside the 
cell. It is clear that there are a variety of steps involved in the aggregation process 
that converts soluble monomers into insoluble ﬁbrillar aggregates (see Fig. 2.1) 
[2.3-2.5]. It has been proposed that the aggregation process begins when a 
polypeptide chain undergoes a structural transition from a native fold into a 
misfolded β-sheet conformation. While for the disease proteins this transition can 
occur under physiological conditions (e.g. due to destabilizing mutations), similar 
changes may be affected in non-disease proteins by more extreme conditions of pH 
or temperature [2.6]. Under appropriate circumstances, misfolded monomers may 
oligomerize into pre-ﬁbrillar assemblies that give rise to mature ﬁbrillar structures. 
Within cells, these aggregates become actively concentrated and sequestered in 
specialized aggresomes at the microtubule organizing center [2.7-2.10]. 
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Recently, a more direct involvement of molecular chaperones in human diseases of 
protein folding has become increasingly evident [2.11-2.14]. 
The mechanisms by which molecular chaperones inﬂuence the development of 
these diseases is beginning to be understood. Mutations that compromise the 
activity of chaperones lead to several rare syndromes (see paragraph 2.1.3). The 
more frequent amyloid-related neurodegenerative diseases are caused by a gain of 
toxic function of misfolded proteins. Toxicity in these disorders may result from an 
imbalance between normal chaperone capacity and production of dangerous protein 
species. Valuable therapeutic strategies could be aimed to increase the expression 
of chaperones capable to suppress the neurotoxicity of these molecules.  
Molecular chaperones, such as Hsp60, Hsp70 and TCP-1 Ring Complex 
(TRiC)/chaperonin containing TCP-1 (CCT), have been implicated as potent 
modulators of misfolding disease [2.11]. These chaperones suppress toxicity of 
disease proteins and modify early events in the aggregation process in a cooperative 
and sequential manner reminiscent of their functions in de novo protein folding. 
Further understanding of the role of molecular chaperones in misfolding disease is 
likely to provide important insight into basic pathomechanistic principles that could 
potentially be exploited for therapeutic purposes. 
 
 
 
2.1.1 Mechanisms of toxicity in aggregation diseases 
 
The exact mechanism by which protein misfolding and aggregation is linked to 
disease is still unclear, but there is increasing evidence that the main toxic agents 
are soluble precursors (monomers or oligomers) of the disease proteins, rather than 
the mature insoluble fibrils into which they develop (see Fig. 2.1-2.2 and [2.15- 
2.23). For instance, recent experiments with a species of the Aβ peptide in an AD 
model have shown that Aβ oligomers, and not the mature amyloid fibrils, are 
neurotoxic [2.19].  
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Additionally, expression of polyQ-expanded huntingtin causes toxicity in a yeast 
model of HD, before insoluble aggregates can be detected [2.23].  
Taken together, these studies suggest that oligomeric precursors of the mature 
fibrils present in a wide variety of misfolding diseases may be the principal agent 
of toxicity. However, the possibility that mature fibrils may also contribute to 
neuronal toxicity should not be ruled out [2.7, 2.24]. There are currently three main 
non-exclusive hypotheses to explain the mechanism of toxicity caused by misfolded 
disease proteins: 
 
- The first, termed ‘the channel hypothesis’, suggests that ring-shaped 
oligomers, exposing hydrophobic surfaces, form early in the aggregation 
process and cause toxicity by forming pores in cellular membranes. The 
formation of such pores has been described under experimental conditions 
Figure 2.2 Protein misfolding and aggregation in different neurodegenerative 
diseases. (a) Schematic diagram showing steps of formation of different abnormal protein 
species after the cellular stress response; (b) schematic diagram of sequential formation of 
different amyloid species; (c) electron micrographs of different species of amyloid beta 
protein; (d) amyloid beta plaques (upper) stained with 4G8 antibody from brain tissue of 
AD mouse model, neurofibrillary tangle (middle), and synaptic (dendritic spine, Golgi-
Cox stain) loss in mouse model of Alzheimer’s disease (lower); (e) tyrosine hydroxylase 
(the indicator of dopaminergic neuron) positive (small arrow) neuronal loss in the 
substantia nigra-pars compacta and tyrosine hydroxylase positive fiber loss in the striatum 
of MPTP-model of Parkinson’s disease. 
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for several aggregation disease proteins, including Aβ-peptide, PrPSc, 
alpha-synuclein, and polyQ-peptides [2.25-2.28].  
- A second disease mechanism stresses aberrant interactions of misfolded 
proteins with other proteins, rendering them non-functional. For example, 
polyQ expanded huntingtin can cause the co-aggregation of several 
transcription factors that contain polyQ sequences in the normal range 
[2.18]. 
-  Finally, the association of aggregating disease proteins with the quality 
control machinery may itself contribute to cellular toxicity. Misfolded 
proteins may sequestrate components of the chaperone and degradation 
systems, reducing their activity in the cell.  
 
 
 
2.1.2 Role of molecular chaperones in Alzheimer’s disease 
 
The principal misfolded proteins in Alzheimer’s disease (AD) are A𝛽 and tau 
[2.29]. The first one is formed from amyloid precursor protein (APP) and deposited 
as amyloid plaques, mostly in extracellular spaces. Tau is the microtubule 
stabilizing protein and when it is hyperphosphorylated accumulates intracellularly 
(and sometimes extracellularly) in neurofibrillary tangles [2.30-2.33].  
Cell free experiments demonstrate that several HSPs (see Table 2.2), alone or in 
synergistic action, are able to significantly slow down or eventually suppress 
protein aggregation involved in severe amyloid diseases. In vivo studies, using 
various animal and cellular models reveal that treatment with specific chaperones 
or their overexpression can ameliorate pathological behavior dysfunction 
characterizing AD pathology [5.11, 5.16-5.19]. 
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Table 2.2: Different heat shock proteins, their localization, functions, and 
involvement in different neurodegenerative diseases. 
 
 
Panchanan Maiti et al., Molecular Chaperone Dysfunction in Neurodegenerative Diseases and Effects of Curcumin BioMed 
Research International Volume 2014, Article ID 495091, 14 pages http://dx.doi.org/10.1155/2014/495091 
 
 
HSPs especially HSP70 can bind with APP and interfere with the APP secretory 
pathway to reduce the production of both A𝛽40 and A𝛽42 [2.34]. Dickey et al. 
reported that HSP70 and HSP90 interact with tau and A𝛽 oligomers and degrade 
them through proteasome system [2.30] (Figure 2.3). Similarly, overexpression of 
HSP70 decreases the amount of insoluble tau, reduces tau phosphorylation, 
increases tau stability, promotes tau binding to microtubules, and decreases the in 
vitro and in vivo toxicity associated with tau protein (Figure 2.3). In contrast, 
downregulation of HSPs by RNA-mediated interference (RNAi) has the opposite 
effect [2.35]. Heat shock cognate 70 (HSC70) together with HSP70 or HSP90 can 
directly bind to tau, independent of its phosphorylation status, thus facilitating 
microtubule polymerization and limiting tau aggregation [2.36]. In addition, HSP90 
and its dependent cochaperones and client proteins may be essential for refolding 
denatured or misfolded tau and A𝛽 [2.36]. Both HSP70 and HSP90 can promote 
HSPs MW 
(kDa) 
Localization Co-localization Function Involved in 
diseases 
Hsp10 10 Mitochondria, 
cytosol, ER, and 
nucleus 
A𝛽 Protein folding AD, MS, and 
tauopathies 
Hsp27 20-30 Cytosol, 
 
Tau, A𝛽, HTT, 
and 
𝛼-synuclein 
Protein 
degradation 
AD, HD, and 
PD 
Hsp40 40 Cytosol, ER, and 
nucleus 
HTT and 
𝛼-synuclein 
Protein folding HD and PD 
Hsp60 60 Mitochondria A𝛽 Prevent protein 
aggregation 
AD 
Hsp70 70 Cytosol, ER, 
nucleus, 
and mitochondria 
A𝛽, HTT, 
𝛼-synuclein, and 
PrPc 
Protein 
folding/unfolding 
AD, HD, PD, 
Prion, 
and MS 
Hsp90 90 Cytosol and ER A𝛽, HTT, 
𝛼-synuclein, and 
PrPc 
Protein 
degradation and 
transcription 
factor 
AD, PD, and 
HD 
Hsp104/110 104-110 Cytosol and ER 𝛼-synuclein and 
PrPc 
Thermal 
tolerance 
PD and prion 
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tau solubility and tau binding to microtubules as well as reduce insoluble tau and 
tau phosphorylation [2.35].  
 
 
 
 
 
 
 
Figure 2.3 Role of molecular chaperones in Alzheimer’s disease. HSP90, HSP70, and 
other client proteins are directly involved in degradation of A𝛽 oligomers and 
phosphorylated tau containing microtubule and help them to degrade either proteasome 
pathway or through autophagy pathway. Failure to dephosphorylate by HSPs leads to 
formation of tau tangle, a hallmark of AD. 
 
 
 
Overexpression of inducible HSP70 reduced soluble and insoluble tau levels in 30-
month-old mice [2.37]. Levels of HSP90 are inversely associated with granular tau 
oligomers and neurofibrillary tangles in AD [2.38] and in a mutant tau-model [2.36] 
(Figure 2.3).  
Current research on the development of therapeutic approaches of intervention in 
amyloid diseases bases on at least four broad approaches:  
 
I) Block the production of the amyloidogenic peptide or protein; 
 
II) Block its ‘‘misfolding'' or transformation from a nonpathogenic monomer or 
low-oligomer to toxic oligomers and polymers; 
 
III) Block the toxic effects of amyloid; 
 
IV) Modulate an auxiliary cellular pathway that affects beneficially one or more of 
the foregoing approaches [5.20-5.22]. 
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2.1.3 Mutations in molecular chaperones as the cause of human diseases 
 
The identification of mutations responsible for a wide variety of inherited human 
diseases has been greatly accelerated in recent years, due to the availability of 
detailed genetic mapping tools developed in the large-scale genome sequencing 
projects. Analysis of the open reading frames (ORFs) that contain mutations has 
revealed alterations in genes encoded for molecular chaperones that may be 
responsible for some complex human diseases. These diseases are likely to be 
caused by the loss of function of one or more chaperone substrate proteins. Some 
examples are described in the following. 
 
- Hsp60 
The hereditary spastic paraplegia SPG13 is caused by a missense mutation of a 
conserved Valine (V72I) residue in the mitochondrial chaperonin Hsp60 [2.39]. 
The disease is characterized by weakness and poor coordination of lower limbs, 
resulting from severe degeneration of the distal ends of long axons in the spinal 
cord [2.40]. The relatively mild phenotype associated with the mutation is rather 
surprising, as Hsp60 is crucial for mitochondrial biogenesis and the missense 
mutation renders Hsp60 partially or completely nonfunctional. It is possible that 
compensatory mechanisms are in place to allow mitochondrial biogenesis without 
functional Hsp60 proteins. 
 
- hMKKS 
Mutations in the cytosolic chaperonin hMKKS have been implicated in 
McKusickKaufman Syndrome (MKKS), characterized by malformations of the 
genital tract, polydactyly and congenital heart disease; and Bradet-Biedel type 6 
Syndrome (BBS6), characterized by obesity, retinal dystrophy, renal 
malformations, learning and behavioral abnormalities and endocrinological 
dysfunction [2.41, 2.42]. hMKKS is 40% similar to human TRiC protein, and is 
known to be expressed during development and in adults, but not much is known 
about its biochemical or structural properties. 
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- TRiC/CCT 
Mutations in human Group II CCT subunits 4 and 5 cause rare debilitating diseases. 
Mutation in the epsilon subunit of the cytosolic chaperonin-containing t-complex 
peptide-1 (Cct5) gene causes autosomal recessive mutilating sensory neuropathy 
with spastic paraplegia. For instance, the His147Arg mutation in human CCT5 
causes mutilating peripheral sensory neuropathy [6.19]. 
 
- The α-crystallins 
α-Crystallins are small HSPs, mutations in which have been linked with two 
diseases: R116C mutation in αA-crystallin is linked to a form of hereditary cataract 
[2.43]; and R120G substitution in αB-Crystallin results in a form of desmin-related 
myopathy (DRM) [2.44]. Although the precise mechanism by which mutant αA-
Crystallin causes cataract is not known, it is predicted that the mutant chaperone 
fails to properly fold other major lens proteins. In the case of DRM, it is known that 
αB-Crystallin specifically interacts with desmin in muscle cells, possibly mediating 
its folding and/or assembly into intermediate filaments [2.45]. 
 
- Tubulin-specific chaperones 
The tubulin-specific chaperone E (cofactor E, TBCE) is an essential chaperone 
required for efficient folding of α-tubulin and its dimerization with β-tubulin. 
Mutations in TBCE lead to a reduction in the amount of available α-tubulin to be 
incorporated into microtubules, causing severe cytoskeletal defects such as aberrant 
polarity of microtubule network. Several severe diseases have been linked with 
mutation in this gene, including HRD (hypoparathyroidism, mental retardation and 
facial dysmorphism), Sanjad–Sakati syndrome, and autosomal recessive Kenny–
Caffrey syndrome (AR-KCS) [2.46]. 
 
- Sacsin 
Sacsin was originally reported to consist of a single gigantic exon spanning 12.8 kb 
with an 11.5-kb ORF, with mutations linked to autosomal recessive spastic ataxia 
of Charlevoix–Saguenay (SACS) [2.47]. Recently, eight exons upstream from the 
original one have been found, and the new ORF has elongated to 13.7 kb. Sequence 
similarity revealed an ubiquitin domain and a DnaJ molecular chaperone homology 
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domain preceding a HEPN (higher eukaryotes and prokaryotes nucleotide binding) 
domain. The mutations R4325X and N4549D that cause SACS are present in the 
DnaJ domain and the HEPN domain, respectively [2.48]. The DnaJ heat shock 
domain is essential for interactions with chaperone Hsp70-like proteins and the 
HEPN domain is implicated in nucleotide binding [2.48]. This raises possibilities 
of Sacsin functioning either directly or indirectly in chaperone mediated protein 
folding.  
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2.2 Molecular Chaperones and Oncogenesis 
 
As described before molecular chaperones constitute a major arm of the proteostasis 
network; they play a central role in the maintenance of protein homeostasis through 
an intricate system of cooperative mechanisms that balance protein biosynthesis, 
folding, translocation, assembly/disassembly, and clearance [2.49, 2.50].  
Increased protein chaperone capacity has been linked to the etiology of many 
diseases including cancer [2.51]. Considerable evidence now exists implicating 
molecular chaperones in the development of cancer. They have been shown to play 
a fundamental role in the molecular mechanisms that lead to the emergence and 
progression of the tumor phenotype. Accordingly, levels of heat-shock factor 1 
(HSF1), a transcriptional regulator of protein homeostasis that activates the 
transcription of HSPs has been shown to be elevated in many cancer cell lines and 
tumors [2.52]. Indeed, the expression of several HSPs is increased in many tumors, 
such that HSPs are prognostic biomarkers in cancer and their overexpression is 
linked to poor survival and response to therapy [2.53]. The sensitivity of a wide 
variety of tumors to inhibitors of HSPs exemplifies the importance of molecular 
chaperones in maintaining survival of cancer cells [2.54].  
Detailed information on the involvement into oncogenesis for the two proteins 
(Hsp60 and TRiC/CCT) that are the subject of this thesis work, are reported in the 
two following paragraphs. 
 
 
2.2.1 Hsp60: Contribution to oncogenesis 
 
Hsp60 in eukaryotes is considered typically a mitochondrial chaperone (also called 
Cpn60) but in the last few years it has become clear that it also occurs in the cytosol, 
the cell surface, the extracellular space and in the peripheral blood [4.4 2.55].  
Studies with prokaryotic models have shown that Hsp60 plays a role in assisting 
nascent polypeptides to reach a native conformation, and that it interacts with 
Hsp10 (which also resides in the mitochondria and is also named Cpn10). In 
addition to its role in polypeptide folding in association with Hsp10, other functions 
and interacting molecules have been identified for Hsp60 in the last several years. 
Some of these newly identified functions are associated with carcinogenesis, 
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specifically with tumor cell survival and proliferation. Thus, assessing the levels of 
Hsp60 in tumor cells and in sera of cancer patients is becoming an attractive area 
of investigation aiming at the development of means for practical applications in 
clinical oncology. Since Hsp60 participates in extracellular molecular interactions 
and cell signalling and also in key intracellular pathways of some types of tumor 
cells, the idea of using Hsp60 in anti-cancer therapy (chaperon-therapy) is being 
investigated. The Hsp could be used either as an anticancer agent alone or in 
combination with tumor antigens, or as target for anti-chaperone compounds 
 
Intracellular Hsp60 
In eukaryotes, Hsp60 typically resides in the organelles mitochondria (chaperonin 
60 or Cpn60) and chloroplasts (in plants), and interacts with Hsp10 (or Cpn10) 
while chaperoning nascent polypeptides as they progress to achieve a functional 
conformation or native status. Hsp60 also interacts with mitochondrial Hsp70 
(mortalin), and with surviving and p53 as it participates in the process of apoptosis. 
The levels of mitochondrial Hsp60 are regulated via complex mechanisms, one of 
which involves a DNA-dependent protein kinase, a molecule that plays a protective 
role against drug-induced apoptosis. In addition to its recognized role in protein 
folding, Hsp60 has been implicated in intracellular protein trafficking, and in 
peptide-hormone signalling in an experimental model of Lyme neuropathy. Hsp60 
can bind and interfere with the functions of various endogenous and exogenous 
proteins. For instance, Hsp60 binds epolactaene, a microbial metabolite that if not 
bound to the chaperone arrests cell cycle and induces the outgrowth of neurites in 
human neuroblastoma cells. 
Lately evidence show that Hsp60 is also found in the cytosol not only after 
mitochondrial release but also independently of such release, and the evidence also 
indicate that both, the mitochondrial and the cytosolic forms of Hsp60 can function 
in pro-survival or pro-apoptotic pathways, depending on the cellular situation [2.55-
2.60]. 
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Surface Hsp60 
Hsp60 can also be found on the surface of normal and tumor cells. Increased 
amounts of Hsp60 on the cell’s surface was considered to serve as a danger signal 
for the immune system leading to the activation and maturation of dendritic cells 
and the generation of a antitumor T-cell response. 
Quite interestingly from the oncological viewpoint, surface Hsp60 has been found 
associated with alpha-3-beta-1 integrin, a protein involved in the adhesion of 
metastatic breast cancer cells to lymph nodes and osteoblasts, with the association 
being inhibited by mizoribine, an Hsp60-binding drug. It has also been shown that 
surface Hsp60 plays a critical part in the metastatization of pancreatic carcinoma, 
and that presence of Hsp60 on the surface of oral tumor cells determines cell lysis 
induced by gamma-deltaT lymphocytes [2.61-2.63]. 
 
Extracellular Hsp60  
In addition to its intracellular and pericellular locations, Hsp60 also occurs in the 
extracellular space and in circulation, a fact that has become firmly established only 
in the last few years, although the mechanisms involved in its secretion, exosomal 
and/or other are not yet understood. Extracellular Hsp60 can interact with a number 
of cell-surface receptors such as CD14, CD40 and Toll-like-receptors (TLRs) can 
cause pro- and anti-inflammatory effects, and can bind to peptides (e.g., tumor-
derived peptide antigens) and present them to immune system cells. When acting 
as a pro-inflammatory agent, Hsp60 induces secretion of cytokines from 
professional antigen presenting cells and causes activation of T cells. Hsp60 can 
also stimulate the maturation of dendritic cells via the TLR-2 and -4 signal-
transduction pathways, synergizing the pro-inflammatory action of IFN-gamma. 
On the other hand, as anti-inflammatory agent, extracellular Hsp60 can be a ligand 
for gamma-delta T lymphocytes in oral tumors, determining anti-tumoral 
immunosuppression. After stimulation by Hsp60, gamma-deltaT cells showed 
downregulation of Fas expression and nitric oxide production, leading to a loss of 
mitochondrial membrane potential and caspase-9 activation, followed by induction 
of lymphocyte-cell death. Extracellular Hsp60 can also enter into the blood stream 
and be found in plasma of healthy subjects [2.64-2.70]. 
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Controversial role of Hsp60 
Most heat shock proteins (HSPs) have pro-survival functions. However, the role of 
HSP60 is somewhat controversial with both pro-survival and pro-apoptotic 
functions reported. In numerous apoptotic systems HSP60 protein accumulates in 
the cytosol. In BMD188-induced cell death, HSP60 accumulates in the cytosol with 
significant mitochondrial release. In contrast, in apoptosis induced by multiple 
other inducers, the cytosolic HSP60 accumulates without an apparent mitochondrial 
release. The short interfering RNA-mediated knockdown experiments revealed that 
in BMD188-induced apoptosis, HSP60 has a pro-death function and that the pro-
death role of HSP60 seems to involve caspase-3 maturation and activation in the 
cytosol. In contrast, HSP60 appears to play a pro-survival role in other apoptotic 
systems where there is no apparent mitochondrial release as its knockdown 
promotes cell death. In these latter apoptotic systems HSP60 does not associate with 
active caspase-3. In both cases, HSP60 does not appreciably interact with Bax. 
Taken together, our results suggest the following: 
1) Cytosolic accumulation of HSP60 represents a common phenomenon during 
apoptosis induction;  
2) Cytosolic HSP60 accumulation during apoptosis occurs either with or without 
apparent mitochondrial release;  
3) The cytosolically accumulated HSP60 possesses either pro-survival or pro-death 
functions, which involves differential interactions with caspase-3. 
Key questions still unanswered pertain to the differences in structure-function 
features that might exist between the mitochondrial HSP60 and the largely 
unexplored cytosolictic Hsp60. Studies on human Hsp60 structure and oligomeric 
state in vitro could help to validate its role in physiological or pathological cases.  
 
 
2.2.2 TRiC/CCT: Contribution to oncogenesis 
 
The contribution of TRiC to cancer has not received as much attention as members 
of HSPs [2.71], but, evidence is now emerging implicating TRiC in the 
pathogenesis of numerous cancers. In the last years, many proteins associated with 
tumorigenesis have been identified as bona fide TRiC clients; these include signal 
transducer and activator transcription (STAT3), cyclins B and E, P53 and Von 
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Hippel-Lindau [2.72]. A recent study suggested that TRiC subunits (in particular 
CCT2 and CCT1) are essential for survival and proliferation of breast cancer [2.73]. 
CCT1 was shown to be transcriptionally modulated by the driver oncogene, 
phosphatidylinositide 3-kinases (PI3K). Whether these observations reflect the 
protein folding function of TRiC complex or a non-chaperoning role of individual 
subunits is not clear; however, individual subunits of TRiC have been shown to 
have protein-folding capacity [2.74]. While higher expression levels of TRiC have 
been associated with tumorigenesis, a recent analysis of cancer cell lines appeared 
to show less correlation between TRiC concentrations and its specific activity. The 
disparity between TRiC concentrations and TRiC activity has been attributed to the 
dynamic partitioning of substrates between TRiC, its co-chaperones, and HSPs that 
seems to be influenced by concentrations of HSP70 within the cell [2.75]. 
TRiC has been estimated to directly assist the folding of as many as 10% of 
cytosolic proteins [2.76, 2.77] and it provides the unique ability to fold certain 
proteins that cannot be folded by simpler chaperone systems. This strict 
requirement of TRiC is also essential for folding proteins involved in oncogenesis. 
This suggests that TRiC plays a potential role in cancer cell development by direct 
modulation of the folding and activity for client proteins related to oncogenesis, 
such as tumor suppressor Von Hippel-Lindau (VHL) [2.78, 2.79] and p53 as well 
as the pro-oncogenic protein STAT3 [2.80, 2.81].  
The main contributions of the Type II Chaperonin, TRiC/CCT, to Oncogenesis are: 
 
- Chaperonin TRiC works as an Assembly Station for the Tumor Suppressor, 
VHL (Von Hippel-Lindau); 
 
- TRiC contributes to STAT Protein Folding and Function; 
 
- Interaction of TRiC with p53 Promotes the Protein Folding and Activity of 
p53; 
 
- TRiC Modulates Cell Cycle Regulatory Proteins; 
 
- Contribution of LOX-1, a newly identified TRiC Substrate, to Inflammation 
and Oncogenesis. 
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It is clear that chaperones are critical mediators of oncogenesis. TRIC activity is 
linked to oncogenesis through its clients-oncoproteins and tumor suppressor 
proteins that have well-established roles in cancer. TRiC may play an important 
role in oncogenesis by modulating cancer cell growth, apoptosis, and genome 
instability. Major advances have been made in clarifying how TRiC folds its 
substrates, but additional work is necessary to elucidate the mechanisms of TRiC 
substrate recognition, which could be exploited to develop strategies for identifying 
new cancer therapies. In addition, because TRiC is required for the proper folding 
of ~10% of the proteome, a systematic approach to the identification of TRiC 
substrates that contribute to the many different types of cancer will be challenging 
Thus, development of new methodologies and further experimental studies are 
warranted to increase our understanding of the role TRiC in cancer development 
and progression. 
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Chapter III 
“Materials and methods” 
 
3.1 Materials  
 
3.1.1 Chaperonins (Group I and II) 
 
The recombinant mitochondrial (mt) and naΪve (p-mt) Hsp60 were obtained from 
ATGen (Seongnam, South Korea) in stock solutions at 16.0 mM (1 mg/ml) (buffer 
20 mM Tris-HCl, pH 8.0, and 10% w/w glycerol). Lyophilized GroEL from 
SIGMA (St. Louis, MO, USA) was dissolved in the same buffer. The experiments 
on the three proteins were conducted at varying protein concentration in the range 
0.04÷0.4mg/ml. The final buffer for all the three proteins was 20 mM Tris-HCl (pH 
8) containing 30mM NaCl and 3% glycerol (w/w). The samples were filtered 
through a series 0.22 μm membrane and 1 MDa Vivaspin filters with 
Polyethersulfone membrane (Sartorius, Germany). Higher protein concentrations 
were obtained with Vivaspin concentrators with Polyethersulfone membrane and 
10 kDa molecular eight cut-offs (Sartorius, Germany). Protein concentration for 
each experiment was determined by the area under a peak from the corresponding 
High Performance Liquid Chromatography (HPLC) chromatogram. Bovine serum 
albumin, used for HPLC calibration, (BSA) was purchased from Sigma and 
dissolved in buffer 50 mM sodium phosphate buffer.  
The recombinant proteins Pf-CD1, Pf-CD1 Ile138His, and Pf-CD1 Ile138Arg, 
were all derived from the Pyrococcus furiosus chaperonin Group II Pf-Cpn 
(Supplementary material A.1) [3.1]. CD1 refers to a C-terminal deletion of the last 
22 residues of Pf. It had been reported that the removed segment is disordered, 
promotes protein solubility and has only minimal effect on protein function and 
stability. Pf-CD1 Ile138His (designated Pf-H for short) represents the wild-type 
humanized version of the archaeal protein since it contains His at the site 
corresponding to that of the human mutation. Pf-CD1 Ile138Arg (designated Pf-R) 
represents the pathogenic human mutant since it features Arg at the mutation site. 
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The wild-type archaeal CCT subunit orthologous gene was amplified from P. 
furiosus genomic DNA, then modified in Escherichia coli to produce the three 
constructs as previously reported [3.1]. Sequences are given in the Supplementary 
material. The pET33b(1) vector (Novagen, Madison, WI, USA) was used for 
recombinant expression in E. coli BL21 (DE3) and inoculated into 15 mL of LB 
medium plus 50 μg/μL kanamycin at 37 °C, and this 15 mL culture was transferred 
into 1 L of ZYM Auto-Induction medium with kanamycin selection 10 h later. Cells 
were grown in 4 L baffled flasks at 200 rpm at 25 °C for 3 days. The cell pellets 
were re-suspended in re-suspension buffer (25 mM Tris-HCl, 200 mM NaCl and 
pH 7.5), 30 % w/v prior to cell disruption using a continuous flow Cell Disrupter 
(TS Series Benchtop, Constant Systems Ltd. GA, USA) and centrifuged at 11,500 
xg for 20 min to collect cellular debris. The supernatant extract was heated to 80 °C 
(Pf-CD1 and Pf-H) or 70 °C (Pf-R) for 30 min and centrifuged at 11,500 xg for 30 
min to remove non-heat tolerant proteins. The supernatant was further puriﬁed to 
homogeneity by anion exchange chromatography (Bio-Rad MiniMacro Prep High 
Q Column, Hercules, CA, USA), using a 200 mM to 1 M NaCl gradient for 30 min 
at 3 mL/min. Pure fractions were concentrated using 30 kDa spin filters (Amicon 
Milipore, Darmstadt, Germany) spun at 3,500 xg for 20 min. Protein homogeneity 
was assessed by running concentrated fractions on 12% SDS-PAGE gel and protein 
concentration was determined by Bradford assay. 
 
 
3.1.2 Abeta amyloid 
 
The lyophilized synthetic peptide Aβ1-40 (Anaspec) was solubilized in NaOH 5 
mM (Sigma-Aldrich), pH 10, sonicated and lyophilized according to Fezoui et al. 
protocol [3.2]. The lyophilized peptide was then dissolved in 20 mM Tris pH 7.7, 
3% glycerol, 30 mM NaCl , and then filtered with two filters in series (Millex-Lg 
filters with a diameter of 0.20 μm and Whatman filters with a diameter of 0.02 μm) 
in order to eliminate large aggregates. The sample preparation was operated in 
asepsis using a cold room at 4 °C. Aβ concentration was determined by tyrosine 
absorption at 276 nm using an extinction coefficient of 1390 cm-1M-1. 
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All other chemicals used in the experiments were purchased from Sigma unless 
specified otherwise 
 
 
3.2 Methods & Characterization 
 
3.2.1 Differential Scanning Calorimetry, DSC 
 
DSC experiments were conducted on a Nano-DSC (TA Instruments, New Castle, 
DE, USA) equipped with 0.3 mL capillary platinum cells. The sample cell was filled 
with 0.3 mL of protein solution and the reference cell with the same volume of 
buffer (we used different buffer in function of the study, see results). Samples and 
buffers were ﬁltered and degassed in vacuum before loading into the DSC cell. 
Baselines were obtained by performing blank buffer-buffer scans. The total 
enthalpy change needed for the complete unfolding, ∆Hcal, was calculated by 
integration of the excess heat capacity of the unfolding transition, CP,trs, over 
temperature in the significant temperature interval: 
∆H𝑐𝑎𝑙 =  ∫ ∆𝐶𝑃,𝑡𝑟𝑠𝑑𝑇
𝑇2
𝑇1
 
Here T1 and T2 represent absolute temperature values before and after the unfolding 
process, respectively. Nano-Analyze TA and MicroCal Origin Pro 8.0 Software 
were used for baseline subtraction and ∆Hcal calculation. 
Thermograms on mitochondrial Hsp60, naïve Hsp60 and GroEL were obtained 
within the temperature range 25 ÷ 90 °C at various scan rate (10 ÷ 90 °C/h). The 
protein concentration was 0.08 ÷ 0.4 mg/ml.  Thermograms on chaperonins Pf-
CD1, Pf-H and Pf-R were obtained within the temperature range 25 ÷ 120 °C at a 
scan rate of 60 °C/h. The protein concentration was 0.1÷ 0.4 mg/ml.  Thermograms 
on α-casein and insulin were carried out within the temperature range 7 ÷ 85 °C, at 
a scan rate of 20 °C/h.  
When discussing results in the following chapters (IV-VII) Tm will indicate the 
apparent melting temperature, i.e., the temperature at which excess unfolding heat 
capacity is maximal.  The calorimetric enthalpy ∆Hcal, which is determined 
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independently of any model will be compared with the van’t Hoff enthalpy (∆Hvh) 
derived by the differential scanning calorimetry data according to the Privalov and 
Khechinashvili procedure, as follows: 
∆𝐻𝑣ℎ = 4𝑅𝑇𝑀
2
 
(∆𝐶𝑃,𝑚𝑎𝑥/∆𝐻𝑐𝑎𝑙) 
Where R is the gas constant.   
 
 
 
3.2.2 Isothermal Titration Calorimetry, ITC 
 
Two models of ITC calorimeters (Nano ITC Low Volume and Nano ITC Standard 
Volume) by TA Instruments were used in the course of the thesis’ work. The 
oligomeric equilibrium of chaperonins GroEL, mitochondrial Hsp60 and its 
precursor native form was studied by using the Nano ITC Low Volume with a 
reaction cell volume of 166µL. The experimental procedure was similar to that 
described in a recent work on the oligomeric equilibrium of the co-chaperonin 
GroES [3.3 - 3.4]. Briefly, the protein solution (20 mM Tris-HCl (pH 8) buffer 
containing 30mM NaCl and 3% w/w glycerol) was loaded into the titration syringe 
at a concentration of 0.4mg/ml, and the reaction cell was filled with buffer solution. 
Prior to use, both protein solutions and buffer were filtered and degassed in vacuum. 
The experiments were carried out at 25 °C. Each titration consisted of 34÷25 
successive injections of 1.5÷2 µL of the protein solution into the reaction cell. The 
time interval between consecutive injections was 5 min and stirring at 300 rpm was 
applied to ensure complete mixing. The heat values were obtained by integrating 
each thermal power peak. Data analysis and modeling were carried out using Nano-
Analyze Data Analysis TA® and MicroCal Origin Pro 7.0 Software. 
The same Nano ITC Low volume was used in investigating the binding reaction 
between the group I chaperonin mt-Hsp60 and amyloid peptide Aβ1-40 at different 
stages of its fibrillization process. The experiments were carried out in buffer 20 
mM Tris-HCl (pH 8), 30mM NaCl, 5mM DTT, and 3% w/w of glycerol   at 25°C. 
Titration experiments consisted in successive 2µL injections (25 steps) of A-β 
solutions (50 µM) into mt-Hsp60 (2 µM), with a time interval between injections 
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of 300 sec. Stirring at 280 rpm should ensure good mixing. All samples were 
degassed before the experiment.  
Binding isotherms were corrected by subtracting both the ligand and protein 
(receptor) dilution isotherms. These are determined by titrating A-β solutions into 
buffer or titrating buffer into mt-Hsp60 solutions. The heat of binding corrected for 
dilution effects is [3.5]: 
 
 
 
 
Data analysis and modeling were carried out by using Nano-Analyze Data Analysis 
TA® and MicroCal Origin 7.0 software. 
For all the experiments, the dependence of the heat of reaction on the mole of titrant 
added conforms to a simple model of one-set binding. The model assumes that there 
is a single independent binding site on each subunit forming 1:1 ligand/protein 
complex. In this case, the analytical solution for the normalized heat associated with 
each injection is: 
 
𝑄𝑖 =
𝑉0∆𝐻
𝑣𝑖𝑛𝑗𝐿0
([𝑃𝐿]𝑖 − [𝑃𝐿]𝑖−1 (1 −
𝑣𝑖𝑛𝑗
𝑉0
)) + 𝑞𝑑 
 
Where V0 is the reaction volume, ∆H is the enthalpy of binding, [PL]i is the 
concentration of protein-ligand complex in the reaction volume after each injection 
i, vinj is the injected volume, L0 is the ligand concentration in the syringe, and qd is 
the background injection heat effect. The concentration of protein-ligand complex 
after each injection i, [PL]i, is calculated by solving and applying the following 
equations: 
 
 
[𝑃]𝑡,𝑖
𝐾[𝐿]𝑖
1 + 𝐾[𝐿]𝑖
+ [𝐿]𝑖 − [𝐿]𝑡,𝑖 = 0 
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[𝑃𝐿]𝑖 = [𝑃]𝑡,𝑖
𝐾[𝐿]𝑖
1 + 𝐾[𝐿]𝑖
 
 
Where K is the equilibrium binding constant, and [P]i and [L]i are equilibrium 
concentrations on protein and ligand, respectively. The total concentrations of 
protein and ligand in the calorimetric cell after each injection i are given by: 
 
[𝑃]𝑡,𝑖 = 𝑃0 (1 −
𝑣𝑖𝑛𝑗
𝑉0
)
𝑖
 
[𝐿]𝑡,𝑖 = 𝐿0 (1 − (1 −
𝑣𝑖𝑛𝑗
𝑉0
)
𝑖
) 
 
Data fit to the model provides the equilibrium constant K and the change of enthalpy 
∆H as fitting parameters. The corresponding changes of free energy, ∆G, and 
entropy, ∆S, are then determined by: 
 
∆𝐺 = −𝑅𝑇𝑙𝑛𝐾 
∆𝐺 = ∆𝐻 − 𝑇∆𝑆 
 
Where R is the gas constant and T  the absolute temperature. 
 
The oligomeric equilibrium for Group II chaperonins Pf-CD1, Pf-H and Pf-R 
was studied by using a Nano ITC Standard Volume (TA Instruments) with a 
reaction cell volume of 1 mL. Prior to use, protein solutions and buffer were filtered 
and degassed in vacuum. The experiments were carried out at 25 °C. The protein 
solution (20mM phosphate, pH 7.5, containing 100 mM NaCl) was loaded into the 
titration syringe at a concentration of 0.3 mg/mL. Each titration consisted of 18-19 
successive injections of 5 µL protein solution into the reaction cell (980 µL) filled 
with buffer only. The time interval between consecutive injections was 5 min and 
stirring at 300 rpm was applied to ensure complete mixing. A new hexadecamer-
monomer equilibrium model was developed to analyze ITC curves.  
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The Nano ITC Standard Volume was also used for experiments on ATP binding 
to Group II chaperonins Pf-CD1, Pf-H and Pf-R. The measurements were carried 
out at 37 °C in 20 mM Tris-HCl, 20 mM MgCl2 and 10 mM KCl (pH 7.6). Prior to 
use, all solutions were degassed under vacuum to eliminate air bubbles. ATP 
concentration was determined by the absorbance at 259 nm using an extinction 
coefﬁcient of 15,400 M-1 cm-1. Titration experiments were performed by successive 
5 μL injections of freshly prepared 200 μM ATP solution into the reaction cell 
(volume 1 ml) filled with the protein solution at 7.5 μM concentration. The volume 
of the reaction cell is, spaced at 5 min intervals (stirring speed was 280 rpm). The 
time interval between consecutive injections was 600 s and stirring rate was 300 
rpm.  Binding isotherms were corrected by subtracting the ligand dilution 
isotherms, determined by titrating ATP solution into buffer. For all three proteins, 
the model of one-set binding well described the dependence of the heat of reaction 
on the mole of titrant added. 
 
3.2.3 Circular Dichroism, CD 
 
CD measurements were performed on a JASCO J-815 (Easton, MD, USA) 
spectropolarimeter equipped with a Peltier unit for the temperature control. Far-UV 
CD spectra (260-190 nm) on chaperonins in solution were recorded at 20 °C with 
0.1 mm quartz cuvettes, using a data pitch of 0.5 nm, a bandwidth of 3 nm, a scan 
rate of 50 nm/min, a response time of 4 s. Each spectrum measurement was obtained 
by averaging over eight scans and subtracting the blank solvent. 
Secondary structure composition and assignments from CD spectra in terms of 
percent of alpha-helix, beta-sheet, turn and random coil content, were obtained by 
CDPro analysis [3.6]. 
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3.2.4 High Performance Liquid Chromatography, HPLC 
 
Size-exclusion chromatography was employed to investigate the effect of mt-Hsp60 
on the fibrillization of the amyloid peptide β1-40.  Chromatographic separations were 
performed with a modular Prominence Shimadzu HPLC device equipped with a 
mobile phase degasser (DGU-20As), a quaternary pump (LC-2010 AT) a 
photodiode array detector (SPD-M20A). A 20 μL sample loop was used for 
analytical measurements and a 500 μL sample loop was employed to design 
collection of Aβ. For both analytical and preparative measurements, samples were 
separated with a Superdex 200 increase (GE Healthcare), at room temperature and 
eluted with a flow of 1 ml min−1 in the sample buffer (20 mM Tris - HCl pH 7.7 
with 3% glycerol and 30 mM NaCl) degassed by an in-line degasser filter (DGU 
20A5). The chromatographic profiles were reported at 280 nm. Analytical 
measurements were used to determine the Hsp60 concentration [3.7]. The column 
was calibrated using two specific calibration kits for both low and high molecular 
weights globular proteins (low code n 28-4038-41; High code n 28-4038-42 - GE 
Healthcare Life Science). The protein used are: Aprotinin MW 6500 Da, 
Ribonuclease A MW 13700 Da , Stoke Radius (SR) 1.64 nm; Carbonic anhydrase 
MW 29.000; Ovalbumin 44000 Da, SR 3.05 nm; Conalbumin MW 75000 Da; 
Aldolase MW 158000 Da, SR 4.81 nm, Ferritin 440000 Da, SR 6.1 nm; 
Tyroglobulin 669000 Da SR 8.5 nm.  
Size-exclusion chromatography was employed to investigate the relative 
distribution size-distribution of oligomers for Group II chaperonins. We used a 
Tosoh TSKgel SuperSW3000 column, 4 μm particle size, 4.6 mm ID × 30 cm 
(Montgomeryville, PA, USA) connected to an Agilent 1200 (Palo Alto, CA, USA) 
equipped with an isocratic pump and photodiode UV detector. In each run, 7 μg of 
sample were eluted over 25 min using 20 mM sodium phosphate containing 100 
mM sodium chloride (pH 7.3) as running buffer. The flow rate was 0.25 mL/min at 
a pressure of 68 bar. Absorbance was monitored at 280 nm. After the UV module, 
the flowpath included a Minidawn Treos (Wyatt Technologies, Santa Barbara, CA, 
USA) multiangle light scattering instrument followed by a REx refractive index 
detector (Wyatt Tecnologies). A dn/dc value of 0.185 was used to determine the 
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concentrations for molecular weight calculations. Data analysis was carried out 
with Astra Software version 5.3.4 (Wyatt Technologies). 
 
3.2.5 Light Scattering, LS 
 
The light scattered intensity and its time autocorrelation function were measured by 
using a Brookhaven BI-9000 correlator and a 50 mW He–Ne laser tuned at λ=632.8 
nm. The samples were filtered through 0.2 μm Millex-LG filters into a dust-free 
quartz cell and placed in the cell compartment of a Brookhaven Instruments BI200-
SM goniometer. The temperature was controlled within 0.1°C using a thermostatic 
recirculating bath.  Measurements were taken at 900 scattering angle. Static light 
scattering data were corrected for the background scattering of the solvent and 
normalized by using toluene as a calibration liquid. In Dynamic light scattering 
experiments, the correlator was operated in the multi-channel mode. The electric 
field autocorrelation function, g(1)(q,t), obtained from the intensity autocorrelation 
function, was analyzed by using CONTIN to determine the distribution of 
relaxation times according to: 
𝑔(1)(𝑞, 𝑡) = ∫ 𝐴(𝛤) exp(−Γ 𝑡) 𝑑Γ 
Where A() denotes the contribution amplitude of the mode with characteristic time 
-1. The latter is related to the translational diffusion coefficient by  = q2DT. The 
hydrodynamic radius RH is obtained by the Stokes–Einstein relationship: 
𝐷𝑇 =
𝑘𝐵𝑇
6𝜋𝜂𝑅𝐻
 
Where kB is the Boltzmann constant, T is the absolute temperature, and η is the 
solvent viscosity 
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3.2.6 Fluorescence Spectroscopy, FS 
 
ThT fluorescence emission was monitored by using a JASCO FP-6500 
spectrometer. The excitation and emission wavelengths were 450 and 485 nm, 
respectively. The slit width was 3 nm. ThT final concentration was 12 μM. The 
sample was placed at 37 °C in the thermostated cell compartment (10 mm). When 
required, a magnetic stirrer at 200 rpm (mod. 300, Rank Brothers Ltd., Cambridge) 
was used. 
 
 
3.2.7 Atomic Force Microscope measurements, AFM 
 
AFM measurements were performed by using a Nanowizard III (JPK Instruments, 
Germany) mounted on an Axio Observer D1 (Carl Zeiss, Germany) or on an Eclips 
Ti (Nikon, Japan) inverted optical microscope. Aliquots of protein solutions were 
deposited onto freshly cleaved mica surfaces (Agar Scientific, Assing, Italy) and 
incubated for up to 20 min before rinsing with deionized water and drying under a 
low pressure nitrogen flow. Imaging of the protein was carried out in intermittent 
contact mode in air by using NCHR silicon cantilever (Nanoworld, Switzerland) 
with nominal spring constant ranging from 21 to 78 N/m and typical resonance 
frequency ranging from 250 to 390 kHz.  
  
 
 
 Dario Spigolon 
 
50 Biophysical investigation on therapeutic proteins (Chaperonins, Hsp60 and CCT/TRiC) involved in human diseases 
Chapter IV 
 
(Dis)assembly and Structural Stability of chaperonins group I 
(GroEL/Hsp60)  
 
 
4.1 Aim and introduction 
 
Heat shock protein (Hsp60) is a molecular chaperone that assists protein folding in 
mitochondria. It is synthesized in the cell cytoplasm as a higher molecular weight 
precursor form (named p-mtHsp60) containing an N-terminal targeting sequence, 
which is cleaved after import into the mitochondrial matrix [4.1, 4.2]. The protein 
deprived of the N-terminal sequence is generally named mt-Hsp60. It has been 
established, and demonstrated by various techniques, Hsp60 can accumulate in the 
cytosol, in various pathological conditions (i.e., cancer and chronic inflammatory 
diseases). The accumulation of cytosolical Hsp60 may occur with or without 
concomitant mitochondrial release, so that the two types of 60 kDa chaperonin 
proteins, (mtHsp60 and its precursor naïve form, p-mtHsp60) could coexist in the 
cytosol [4.3]. The precursor naïve Hsp60 is able to assemble in both heptamers and 
tetradecamers over a wide range of concentration [4.4]. Key questions still 
unanswered pertain to the differences in structure-function features that might exist 
between the well-studied prokaryotic homolog GroEL and the largely unexplored 
eukaryotic Hsp60 proteins. Moreover, studies on human Hsp60 structure and 
oligomeric state in vitro could help to validate its role in physiological or 
pathological cases. In order to pursue this goal, High-sensitivity Nano differential 
scanning calorimetry (Nano-DSC), Nano Isothermal Titration calorimetry (Nano-
ITC), Circular Dichroism (CD), and High Performance Liquid Chromatography 
(HPLC) were applied for the first time to study the (dis)assembly, structural and 
thermal stability of chaperonins group I Hsp60 either  in its precursor or 
mitochondrial form. 
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4.2 Results & Discussion 
 
Thermal stability of GroEL and Hsp60s  
 
Owing to the ready availability and the marked stability of the bacterial chaperonin 
system, most of our understanding of chaperonin structure and function comes from 
investigation of the GroE chaperonin proteins (GroEL and GroES) from 
Escherichia coli. Numerous previous studies have revealed that there are some 
significant differences between the bacterial and the mitochondrial chaperonins 
with respect to their oligomeric state, the effect of nucleotides on their interaction 
with co-chaperonins and their ability to function with co-chaperonins from different 
sources [4.5, 4.6]. 
The purpose of the DSC experiments was to compare (for the first time by DSC and 
CD performed under the same conditions) the thermal unfolding of GroEL, 
mtHsp60 and its precursor naïve form, p-mtHsp60. Results in Fig. 4.1 show that for 
all protein systems the oligomer denaturation is a two-stage process, as also 
evidenced by the ratio between calorimetric enthalpy and van’t Hoff  that is, as 
expected by the curve shapes, larger than 1.1 (see Table 4.1). Accordingly, data fit 
with a two-state unfolding model well reproduces the experimental curve. The 
relative thermodynamic parameters are also reported in Tab. 4.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Human Hsp60s (mitochondrial and precursor form, respectively blue and 
green) compared to bacterial homolog GroEL (red), at the same condition, scan rate 
30°C/hr, protein concentration (0,4mg/ml): a) DSC data. The profile of three proteins 
contained two distinct endotherms, and was fitted in terms of two coupled transitions. This 
fitting had the lowest chi square of different models tested independently (data not shown). 
b) CD data: Characterization of unfolding by following the change in ellipticity at a single 
wavelength (225 nm) as a function of temperature. 
 
A 
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Table 4.1 Parameters of GroEL, mt and p-mtHsp60 heat denaturation 
 
 
 
 
 
 
 
 
 
 
 
∆𝐻𝐶𝑎𝑙 and  ∆𝐻𝒗𝒉 per subunit 
aR=∆𝐻𝐶𝑎𝑙 /∆𝐻𝒗𝒉 
 
The three proteins have different thermal and structure stability, in fact they unfold 
with different melting temperatures (Tm) and different calorimetric enthalpy 
changes (∆HCal).  GroEL shows up more stability in respect to mtHsp60 and p-
mtHsp60. Indeed, the calorimetric enthalpy of GroEL transition (1205 kJ/mol) is 
twice larger than that of the precursor form (593 kJ/mol) and about 10-fold the 
mitochondrial one (124 kJ/mol). The proteins display different cooperativity, too. 
The sharpness of the transition peak can be measured as the Full Width at Half 
Maximum (FWHM), which is an index of the cooperative nature (two-state or 
multistate process) of the transition from native to denatured state. GroEL transition 
shows the highest cooperativity, as its unfolding transition occurs within a narrow 
temperature range (FWHM of GroEL denaturation is about 4.69, versus 9 and 6 for 
p-mt and mtHsp60 respectively). Results from CD measurements as a function of 
temperature at the same conditions, are in agreement with DSC data (Fig. 4.4). 
Indeed, as highlighted by the shape and inflection point of the sigmoidal curve, 
GroEL seems to unfold extremely cooperatively while both p-mt-Hsp60 and mt-
Hsp60 unfold gradually (particularly mt-Hsp60). Thus, it appears that the evolution 
of GroEL has generated such extreme cooperativity in unfolding in order to 
maximize its functional lifetime under harsh conditions. In turn, mt-Hsp60 is less 
stable than p-mt-Hp60, with a lower cooperativity in the thermal denaturation 
transition. We think that the main biological indication from these results is that a 
major versatility and flexibility of eukaryotic (particularly mtHsp60) than 
prokaryotic proteins is closely related to the evolutionary history of a complex. 
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Thermal investigation and analysis on (dis)assembly and unfolding of GroEL 
and Hsp60s 
 
As a large mess of information in the literature concerns the unfolding of GroEL, 
initial experiments were performed to establish whether DSC measurements on 
structure and thermal stability (in the absence of Mg-ATP) of GroEL  could validate 
basic findings achieved through other techniques, such as light and X-ray scattering 
[4.7-4.9], urea gradient gel electrophoresis [4.10], etc.  
We found that for GroEL (as for both mt-Hsp60 and p-mt Hsp60, see table 4.1) the 
ratio between calorimetric enthalpy and van’t Hoff per subunit is larger than 1.1 
(the characteristic value expected for a two state thermal denaturing transition 
[4.11]). Observing that ∆𝐻𝒗𝒉<∆𝐻𝐶𝑎𝑙  indicates that most likely there is an unfolding 
intermediate. The asymmetry observed in the DSC thermograms is evident for all 
proteins, and DSC unfolding peaks are skewed at temperatures below the transition 
midpoint (𝑇𝑚), where the transition is less sharp and deviates more from the two-
state fit (Fig. 4.1). Accordingly, best fitting with a two-state unfolding model well 
reproduces the experimental curves for all three proteins (Fig. 4.1). 
The existence of partially unfolded species before and around the transition mid-
point but not after it [4.14-4.16] is in agreement with previous data obtained for 
GroEL by transverse urea gradient gel electrophoresis. In fact, the denaturation of 
GroEL from the urea-unfolded state in the absence of Mg-ATP [4.10, 4.17] is 
associated to a two-stage variation in the hydrodynamic volume, which firstly 
decreases in the region of 2 M urea and then increases noticeably at larger urea 
concentration. Moreover, it was previously shown by ultracentrifugation, circular 
dichroism, light scattering, intrinsic tyrosine fluorescence and fluorescence of the 
hydrophobic probe, 1,1’-bis(4-anilino)naphthalene-5,5’-disulfonic acid (bisANS) 
[4.18] that urea induces dissociation of the oligomer GroEL [4.16] at moderate 
concentration and complete dissociation of GroEL into monomers at concentration 
larger than 2.6 M.  
To ascertain the hypothesis of unfolding couple to oligomers dissociation, we made 
DSC measurements on GroEL samples at different protein concentration (at the 
same scan rate Fig. 4.2). We observed that the melting temperature and the 
calorimetric enthalpy increases with protein concentration as expected for a 
transition coupled to dissociation [4.12].  
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DSC thermograms at various protein concentrations were fitted in terms of two 
coupled transitions. The contributions of each transition to the total enthalpy are 
shown in the right panel of Fig. 4.2 as a function of protein concentration.  It is 
evident that the enthalpy of dissociation of oligomeric GroEL into subunits 
(partially unfolded under dissociation) increases with protein concentration, while 
the enthalpy of unfolding remains constant (this is in agreement with light scattering 
too, where there is a drastic decrease in intensities of light, data not shown). Thus, 
our DSC results are consistent with the hypothesis of a dissociation (thermally 
induced) of the oligomeric protein into monomers that precedes the unfolding. 
Complementary CD measurements were done to follow the change in the secondary 
structure due to unfolding at the same scan rate used for DSC (30°C/hr). The 
dependence of GroEL ellipticity (measured at 225nm) in the region of absorption 
of peptide bonds as a function of temperature is shown in Fig. 4.3 (left panel). Data 
show a slow decrease in the amplitude of circular dichroism and a sharp change in 
the range from 60 to 75 with a midpoint in the region of 67÷70 °C. CD spectra at 
different temperatures are shown in the right panel of the same figure.  
 
 
Figure 4.2 Thermal unfolding of GroEL at different protein concentrations. Left panel: 
DSC profiles for 1.4 μM (black), 2.3 μM (blue), 4.2 μM (red), 7 μM (green) protein 
concentration. Right panel: enthalpy contributions of oligomers dissociation (ΔHdiss) and 
monomers unfolding (ΔHunfolding), obtained by data fitting in terms of two coupled transitions, 
as a function of GroEL concentration. 
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Consistently with DSC results, the initial slow decrease of CD signal at 225 nm and 
any deviation from the native state spectrum (green spectrum in Fig. 4.3 b) suggest 
partial unfolding of the protein. In fact, an additional loss of helical CD takes place 
from 25 to 60°C (cyan spectrum) that could be attributed to a partial loss of 
secondary structure associated to the oligomers dissociation.  The sharp decrease 
between 67°C and 75°C is conceivably due to the unfolding of protein subunits, 
since by 75-76 the protein has lost most of its detectable secondary structure (Fig. 
4.3 b). It is worth to note that the major variations of secondary structures are 
observed in the temperature interval where the monomers thermal unfolding falls.  
Results by means HPLC separations pointed out later in the text, furtherly confirm 
our data interpretation. 
Results for the unfolding of p-mtHsp60 at different concentration as detected by 
DSC and CD measurements are reported in Fig. 4.4 and Fig. 4.5. Similarly to what 
observed for GroEL unfolding, DSC thermograms are skewed towards the low 
temperature side of the transition and are well described by two coupled transition 
model.  Deviations from the native state CD spectrum (black spectrum in Fig. 4.4 
b) indicate partial unfolding of the protein, and additional loss of helical CD from 
45 to 55°C (cyan spectrum). At temperature above 55°C the protein has lost most 
Figure 4.3 CD results for GroEL unfolding. Panel A: dependence of GroEL ellipticity 
(measured at 225 nm) on temperature (at 30°C/h scan rate). Panel B: CD spectra in the 
absorption area of peptide bonds at different temperature, green curve (25°C),  cyan 
(60°C), magenta (65°C), red (70°C), black (75°C). Samples contained 2.3 μM GroEL in 
20 mM Tris-HCl (pH 8), 30mM NaCl, and 3% glycerol (w/w).  Signals of the buffer blank 
at different temperature were subtracted from the corresponding samples.  
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of its detectable secondary structure, in agreement with DSC results. Measurements 
at different protein concentration show that both the melting temperature and 
calorimetric enthalpy increase with protein concentration as expected for a 
transition coupled to dissociation. Thus, our results demonstrate that the unfolding 
of bacterial and human Hsp60 is coupled with the dissociation of the oligomeric 
protein. At the best of our knowledge, this result is new and original. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4.5 A) Thermal unfolding of p-mtHsp60 at different protein concentrations: dark 
cyan (1.4 μM), black (2.3 μM), red (4.2 μM), blue (7 μM). B) Dependence of p-mtHsp60 
ellipticity measured at 225 nm at different concentrations as a function of temperature 
(30°C/hr). The interpolated sigmoidal curves are drawn as eye guides. 
 
Figure 4.4 Thermal unfolding of p-mtHsp60 followed by DSC and CD. A) p-mtHsp60 
(7 μM) shows a proﬁle with two distinct endotherms.  B) CD spectra in the absorption area 
of peptide bonds at different temperature: black curve (25°C), red (35°C), blue (45°C), 
dark cyan (55°C),  magenta (65°C), dark yellow (75°C), navy (85°C). Samples contained 
7 μM p-mtHsp60 in 20 mM Tris-HCl (pH 8), 30mM NaCl, and 3% glycerol (w/w). 
 
B A 
B A 
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Due to the very low intensity of signal detected by the nano-DSC it was not possible 
to investigate the same range of concentrations in the case of mt-Hsp60. However, 
CD and DSC results (Fig. 4.1b and Fig. 4.6) indicate that the thermal unfolding can 
be similar to that observed for GroEL and p-mt-Hsp60. Results from SEC-HPLC 
presented in the following (see figures 4.7-4.9) confirm the presence of different 
oligomeric species in equilibrium. In comparison with p-mt-Hsp60, mt-Hsp60 in 
the native state is less rich in tetradecamers, and this can account for the lower total 
enthalpy of denaturation.    
.    
  
 
 
 
 
 
 
 
 
Figure 4.6 Thermal unfolding of mtHsp60 followed by DSC and CD. A) mt-Hsp60 (7 
μM) had a proﬁle with two distinct endotherms that was ﬁtted with two coupled transitions 
model.  B) CD spectra in the absorption area of peptide bonds of mtHsp60 at 25°C (black 
curve) and 70°C (red curve). 
 
 
 
HPLC investigation on (dis)assembly of GroEL and Hsp60s  
 
A variety of conditions destabilize GroEL tetradecamers, favoring dissociation to 
monomers, such as moderate urea concentration [4.26], high hydrostatic pressure 
[4.27], presence of nucleotides and adsorption onto ion-exchange resins [4.28], and 
replacement of Lysine 3 at the N-terminus [4.29]. The GroEL N-terminal region is 
located in the subunit interface and is involved in links that stabilize the protein’s 
quaternary structure. Moreover, mutations in the region encompassing the first 4 
amino acids of the mtHsp60 N-terminal region destabilize the protein oligomeric 
state causing its disassembly at low protein concentrations [4.30]. 
B A 
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We made chromatographic separations at HPLC to probe qualitatively and 
quantitatively the dissociation of the proteins (GroEL and Hsp60) thermally 
induced, using a superdex increase 200 10/30 GL size exclusion columns (see 
material and methods). 
As highlighted before, in our DSC and CD results there be a partially unfolding of 
GroEL, that leads first to dissociation (thermally induced) of the protein 
tetradecameric structure to heptamers and monomers, and it would be consistent 
with HPLC separations. In fact, for GroEL, we saw in the region of the dissociation 
thermally induced (light green curve), a dissociation in heptamers and monomers 
(see retention time from 8 to 13 in the panel on the right of Fig.4.7). 
 
 
 
 
  
 
   
  
 
 
 
 
 
 
 
For p-mtHsp60, in the region of the dissociation thermally induced, we saw a clear 
dissociation of tetradecamers in heptamers (Fig. 4.8), from 30% to 50%. While in 
the case of mt-Hsp60 just at room temperature 25°C is evident the dynamic 
equilibrium between tetradecamers heptamers and monomers (Fig. 4.9). 
 
Figure 4.7 GroEL (3,5μM) chromatographic separations at HPLC. Sample scanned 
30°C/hr till different temperatures: Native protein (red curve), T=25°C; on the peak of the 
deconvolution of dissociation (light green), T=69°C; after the melting point (blue), T =72°C, 
and at the end of the transition, T=74°C (dark green). 
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Figure 4.8  P-mtHsp60 (1μM) chromatographic separations at HPLC. Sample scanned 
30°C/hr: Native protein (black curve), T=25°C; on the peak of the deconvolution of 
dissociation (light green), T=62°C. 
 
Figure 4.9 Mt-Hsp60 chromatographic separations at HPLC at 25°C. 
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The Tetradecamer-Heptamer-Monomer Dissociation/Unfolded Model 
(THMDU model) 
 
To gain major information on the processes responsible for the DSC signal recorded 
for the three proteins upon a temperature scan, we developed an ad hoc model. It 
assumes a first dissociation of tetradecamers into heptamers followed by 
dissociation of heptamers into monomers simultaneous with monomer unfolding. 
The Tetradecamer-Heptamer-Monomer Dissociation/Unfolded Model (Eqn 1) was 
adapted and used for the analysis of the DSC curves. All the equations and 
thermodynamic parameters are given in terms of moles of protein monomer. At any 
given total protein concentration, Pt, the molar fractions of the polypeptide chains 
forming the native Tetradecamer (FT), the heptamer fraction (FH) the unfolded 
monomer (FM) and the equilibrium constants Kd1 and Kd2 are combined in the 
following expression: 
 
 
Chemical balance 
𝑇 ↔ 2𝐻 ↔ 14𝑀 
M≈U 
𝐾𝑑1 =
[𝐻]2
[𝑇]
               𝐾𝑑2 =
[𝑀]7
[𝐻]
 
𝐹𝑀 =
[𝑀] 
𝑃𝑡
    𝐹𝐻 =
7[𝐻] 
𝑃𝑡
    𝐹𝑇 =
14[𝑇] 
𝑃𝑡
 
 
As 1 = 𝐹𝑀 + 𝐹𝐻 +  𝐹𝑇 , and considering the mass balance 𝑃𝑡 = 𝑀
 +  7𝐻 + 14𝑇 
 
We obtained: 
𝑃𝑡 = 𝑀
 +  7
[𝑀]7
𝐾𝑑2
+ 14
[𝐻]2
𝐾𝑑1
= 𝑀 +  7
[𝑀]7
𝐾𝑑2
+ 14
[𝑀]14
𝐾𝑑1𝐾𝑑2 
2 
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7
[𝑀]7
𝐾𝑑2
+ 14
[𝑀]14
𝐾𝑑1𝐾𝑑2 
2 + 𝑀
 − 𝑃𝑡 = 0 
 
14
𝑃𝑡
14
𝐾𝑑1𝐾𝑑2 
2
𝑃𝑡
14
𝑃𝑡
14 + 7
[𝑀]7
𝐾𝑑2
𝑃𝑡
7
𝑃𝑡
7 + 𝑀
𝑃𝑡
 
𝑃𝑡
 
 
− 𝑃𝑡 = 0 
 
 
14
[𝑃𝑡]
14
𝐾𝑑1𝐾𝑑2 
2 𝐹𝑀
14 + 7
𝑃𝑡
7
𝐾𝑑2
𝐹𝑀
7 + 𝑃𝑡𝐹𝑀
 − 𝑃𝑡 = 0 
 
Solving this equation leads to FM. The enthalpy of the system will be: 
 
∆Hext=Fmonomer*∆H2+Fheptamer*∆H1; 
 
Where ∆H1 is the unfolding enthalpy change. The derivative of this expression with 
respect to temperature at a constant pressure gives the heat capacity of the protein, 
Cp: 
 
Cp=(dHext-dHexp)/(Tt-Tp)-Fmonomer*dCpd-Fheptamer*dCpu+Cp0 
 
 
The Fig. 4.10 shows the fit and the fraction of the different populations as a function 
of temperature for GroEL at different protein concentrations. The corresponding 
thermodynamic parameters are reported in Table-4.2.   
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Table 4.2-Thermodynamic parameters obtained by fitting DSC thermograms of 
GroEl  with THMDU model 
 
 
 
 
 
 
 
 
 
 
 
We found a negative ∆Cp for the ring dissociation. ΔCp could be negative when 
transient interactions are involved (as it occurs for tetradecamer-heptamer transition 
in GroEL) and the proportion of hydrophobic-to-hydrophilic (or apolar-to-polar) 
GroEL  
Concentration (μM) 
1.4 2.3 4.2 
T1/2 (Tetradec. conversion) (°C) 
 
67.67 68.7 69.5 
∆H1 (cal/mol) 
 
62920 63977 98389 
∆H2 (cal/mol) 
 
162160 163512 168458 
∆Cp1(cal/mol K) 
 
-2560 -3270 -1204 
∆Cp2 (cal/mol K) 
 
349 370 769 
Figure 4.10 On the left: DSC thermograms for GroEL (at different concentrations, black 1.4 
μM, blue 2.3 μM, red 4.2 μM). Symbols represent the experimental data. The continuous lines 
are the fit with Tetradecamer-Heptamer-Monomer Dissociation/Unfolded Model. On the 
right: Fraction of the different populations in function of the temperature as obtained by the 
model. 
Tetradecamer 
Heptamer 
Monomer 
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surface ratio is more shifted to the hydrophilic component.  Most of polar amino-
acids presented in the GroEL monomer (on 548 a.a. 286 are apolar and 262 are 
polar) are in the equatorial domain (see Fig. 4.11) that is in the interaction surface 
for both heptamers. The equatorial domains are located at the interface of 
the cis and trans rings (residues 6-133, 409-523). In the residues 409-523, 58 
amino acids are polar and 57 are apolar, while in the residues 6-133, 65 are apolar 
and 63 are polar.  
The  Figure 4.11  shows the GroEL tetradecamer complex obtained by Pymol. Each 
atom is represented as a sphere of Van der Waals radius; in light cyan are shown 
the apolar amino acids, while in dark cyan the polar ones. Most of polar amino acids 
are located in the equatorial domain. The panel on the right side shows the surface 
of the interface from one of the heptamers. There is a predominance of polar 
residues, similar to the polar/apolar distribution on the lateral surface (permanently 
exposed to solvent) and the interface with the chaperonin GroES (transiently 
exposed to solvent). The predominance in polar residues provides the structural and 
energetic basis for establishing transient and/or dynamical interactions between the 
two heptamers. In addition, polar residues contribute to a negative heptamer 
dissociation heat capacity (as observed from DSC results). 
 
 
 
 
 
   
 
 
 
 
 
 
 
Figure 4.11 GroEL tetradecamer complex obtained by Pymol. Apolar residues are shown 
in light cyan, polar residues in dark cyan. 
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Results of DSC data fitting with THMDU model for p-mtHsp60 and mtHsp60 are 
reported, respectively in Figs. 4.12, 4.13 and Tables-4.3, 4.4. As it occurs for 
tetradecamer-heptamer transition in GroEL, a negative ∆Cp of ring dissociation was 
obtained for both p-mtHsp60 and mtHsp60 (Table 4.3 and 4.4), implying that 
transient interactions are involved for the human homologue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 On the left: DSC thermograms for p-mt Hsp60 (at different concentrations, black 
1.4 μM, blue 2.3 μM, red 4.2 μM). Symbols represent the experimental data. The continuous 
lines are the fit with Tetradecamer-Heptamer-Monomer Dissociation/Unfolded Model. On the 
right: Fraction of the different populations in function of the temperature as obtained by the 
model. 
 
 Fit with Tetradecamer-Heptamer-Monomer Dissociation/Unfolded Model. On the right: 
Fraction of the different populations in function of temperature. 
Tetradecamer 
Monomer 
Heptamer 
Figure 4.13 On the left: DSC thermogram for mt-Hsp60 at 7 μM. Symbols represent the 
experimental data. The continuous lines is the fit with Tetradecamer-Heptamer-Monomer 
Dissociation/Unfolded Model. On the right: Fraction of the different populations in function of 
the temperature as obtained by the model.  
Heptamer 
Tetradecamer 
Monomer 
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Table 4.3-Thermodynamic parameters obtained by Fit with THMDU model for  
p-mtHsp60 
 
 
 
 
 
 
 
 
 
Table 4.4-Thermodynamic parameters obtained by Fit with THMDU model for  
mtHsp60 
 
 
 
 
 
 
 
 
 
The fit quality for all three proteins (GroEL and p-mt and mtHsp60) at the same 
concentration is illustrated in Fig. 4.14. The relative thermodynamic parameters are 
compared in table 4.5. 
 
 
 
p-mtHsp60 
Concentration (μM) 
1 2 4 7 
T1/2 (Tetradec. conversion) (°C) 
 
59.3 60 59.5 62.7 
∆H1 (cal/mol) 
 
1500 1500 3428 11580 
∆H2 (cal/mol) 
 
147663 122537 118220 122534 
∆Cp1(cal/mol K) 
 
-1254 -1154 -1601 -1492 
∆Cp2 (cal/mol K) 
 
2503 1597 942 847 
mtHsp60 
Concentration (μM) 
7 
T1/2 (Tetradec. conversion) (°C) 
 
59 
∆H1 (cal/mol) 
 
518 
∆H2 (cal/mol) 
 
117593 
∆Cp1(cal/mol K) 
 
-921 
∆Cp2 (cal/mol K) 
 
2572 
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 GroEL/Hsp60 (7μM)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5- Comparison of the Thermodynamic parameters obtained by Fit with 
THMDU model for the three proteins 
 
 
 
 
 
 
Protein (7 μM) GroEL (Bacterial 
Hsp60) 
p-mt Hsp60 mt Hsp60 
T1/2 (Tetradec. conversion) (°C) 69.3 62.7 59 
∆H1 (cal/mol) 
 
81929.2 11580 518 
∆H2 (cal/mol) 
 
159517 122534 117593 
∆Cp1(cal/mol K) 
 
-1122 -1492 -921 
∆Cp2 (cal/mol K) 
 
1913 847 2572 
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Figure 4.14 Experimental DSC thermograms and best fit with Tetradecamer-Heptamer-
Monomer Dissociation/Unfolded Model for GroEL (red curve), p-mt Hsp60 (green curve) 
and mt Hsp60 (blue curve). 
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Further investigation of (dis)assembly and unfolding of GroEL and Hsp60s: 
dealing with irreversibility 
 
By literature and by our own results, we know that partial unfolding of GroEL leads 
first to the dissociation of the oligomeric protein. Considering this point, we tried 
to study separately the oligomer dissociation and monomer unfolding by combined 
DSC and by HPLC measurements. We stop the DSC experiment to 66°C, in the 
region of the thermally induced oligomers dissociation (and partially unfolding) and 
then rescan again from 25 to 85°C (Fig. 4.15). We obtained a transition peak very 
similar to the second peak (assigned to unfolding) obtained from deconvolution of 
the original DSC signal for a fresh protein sample.  
 
 
 
 
 
 
 
 
 
 
 
 
 
We evaluated this transition by comparing  ∆𝐻𝐶𝑎𝑙  with ∆𝐻𝑣ℎ  to assess whether the 
transition occurs as a two-state or multistate process. Our system undergoes 
cooperative two-state unfolding with ∆𝐻𝐶𝑎𝑙 / ∆𝐻𝒗𝒉 ≈ 1, so the transition occurs in 
a two-state mode. A closer inspection of the peak assigned to unfolding was then 
performed for taking into account partial irreversibility of the unfolding process. 
Irreversible protein denaturation is thought to involve, at least, two steps: (a) 
reversible unfolding of the native protein (N); (b) irreversible alteration of the 
unfolded protein (U) to yield a final state (F) that is unable to fold back to the native 
Figure 4.15 DSC thermogram for a sample of GroEL firstly brought to 66°C at  30°C/hr 
scan rate and then re-cooled at room temperature (black curve). The red curve represents 
the second peak (assigned to unfolding) obtained from deconvolution of the original DSC 
signal for a fresh protein sample. 
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one. There are several processes responsible for the irreversible step (aggregation, 
autolysis, chemical alteration of residues, etc.) [4.19, 4.20].  
The two-step nature of irreversible denaturation is depicted in the following 
simplified scheme, which is usually known as the Lumry and Eyring model [4.21]: 
 
𝑁
𝐾
⇔ 𝑈
𝑘
→ 𝐹 
 
Where K and k are the unfolding equilibrium constant and the rate constant, 
respectively. We will assume that chemical equilibrium between N and U is always 
established and that the unfolding enthalpy,∆𝐻𝑈, is constant. Then, the temperature 
dependence of K, can be expressed as, 
 
1) 𝐾 = [𝑈]
[𝑁]
=
𝑥𝑈
𝑥𝑁
= 𝑒𝑥𝑝 {−
∆𝐻𝑈
𝑅
[
1
𝑇
−
1
𝑇1/2
]} 
 
Where xu and xN stand for the molar fractions of unfolded and native states and T1/2 
(or Tm) is the temperature at which K= 1. The apparent excess enthalpy,〈∆𝐻〉, is 
given by, 
 
2) 〈∆𝐻〉 = 𝑥𝑈 ∆𝐻𝑈  + 𝑥𝐹∆𝐻  
 
Where ∆Hu and ∆𝐻 are, respectively, the enthalpies of the states U and F (taking 
N as the reference state). Note that the enthalpy of the final state (∆𝐻) is equal to 
the calorimetric enthalpy of the DSC transition, because eventually all protein 
molecules will be found in the final state. We made the reasonable assumption that 
the processes responsible for the irreversible step have much lower enthalpy than 
the cooperative unfolding (see Fig. 4.16). Many authors have previously supported 
the applicability of the equilibrium thermodynamics analysis to irreversible DSC 
transitions [4.22-4.24]. Accordingly, we will assume that the enthalpy of the 𝑈 →
𝐹 transition is zero and that, therefore, ∆𝐻𝑈 =  ∆𝐻 . Eq. 2 can be written as, 
 
3) 〈∆𝐻〉 = ∆𝐻(𝑥𝑈 + 𝑥𝐹) = ∆𝐻(1 − 𝑥𝑁)   
 
and the apparent, excess heat capacity, Cpex is given by, 
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4) Cpex = −∆𝐻
𝑑𝑥𝑁
𝑑𝑇
 
as ∆𝐻 has been assumed to be constant. Finally, 𝑑𝑥𝑁/𝑑𝑇 is substituted in Eq. 4 to 
yield: 
 
5) Cpex =
𝐾∆𝐻
(𝐾+1)2
 (
𝑘
𝑣
+
∆𝐻
𝑅𝑇2
) 𝑒𝑥𝑝 {−
1
𝑣
∫
𝑘𝐾
𝐾+1
𝑑𝑇
𝑇 
𝑇0
} 
 
 
Where 𝑣 is the constant scanning rate (𝑣 = 𝑑𝑇/𝑑𝑡). It is interesting that the 
equation corresponding to a two-state reversible unfolding: 
 
 
Cp
ex =
𝐾∆𝐻2
𝑅𝑇2(𝐾 + 1)2
  
 
 
Can be derived from Eq. 5) either by setting k = 0 at any temperature (the 
irreversible process does not take place) or by setting 1/𝑣 = 0 (infinite scanning 
rate). In spite of that, it is clear that direct application of equilibrium 
thermodynamics to the irreversible transition would not lead to large errors [4.19]. 
We obtained (with a𝑣 = 30°C/hr) an unfolding enthalpy (∆𝐻𝑈) of 660 kJ/mol and 
an unfolding temperature of 70.2 °C. So, the second stage is associated with further 
unfolding of GroEL and it occurs in a two-state mode (two-state folding/unfolding 
model). Actually, the irreversible step in the thermal denaturation of GroEL 
subunits takes place (with negligible thermal effect) at temperatures somewhat 
above than those corresponding to the DSC transition; therefore, we were able to 
study the irreversible step separately and we found an energy of activation of ≈32 
kJ/mol, that correspond to the irreversible step itself (Fig. 4.16, b).  
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Values for the free energy ∆Gtrs(T) were determined by analyzing the experimental 
data in terms of a two-state transition model. The DSC values for ∆Gtrs(T) are 
extrapolated to room temperature of 298.15 K, and we used Gibbs–Helmholtz 
equation: 
 
∆𝐺(𝑇) = ∆𝐻𝑚 (1 −
𝑇
𝑇𝑚
) − ∆𝐶𝑝(𝑇𝑚 − 𝑇 + 𝑇𝑙𝑛 (
𝑇
𝑇𝑚
)) 
 
The change in heat capacity ∆Cp for the unfolding was 2.62 ± 0.13 kcal mol-1 K-1. 
We found a ∆Gtrs of 50 kJ/mol, in accordance with value obtaining by chemical 
denaturation [4.25].  
 
Figure 4.16 Thermal unfolding of GroEL subunits after thermally induced 
dissociation of oligomers: on the top and residuals of the Fit on the bottom. A) The 
blue dashed curve is a fit of these data to a simple two-state unfolding model. B)  The 
red curve curve is a fit of these data to a simple two-state unfolding model, containing 
the irreversible step (green transition) in the thermal denaturation. 
 
 
B A 
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We made the same experiment for Hsp60 (precursor form, Fig. 4.17), obtaining 
(with a 𝑣 = 30°C/hr) an unfolding enthalpy (∆𝐻𝑈) of 490 kJ/mol, an unfolding 
temperature of 65°C and an energy of activation of the irreversible step of ≈52 
kJ/mol. We found a ∆Gtrs of 40 kJ/mol (400kJ/mol dHm; dCp about 3kJ/Kmol), in 
accordance with value obtaining by chemical denaturation [4.25]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investigation by ITC 
 
We made ITC dilution measurements to probe the dissociation of the protein [4.31]. 
The first set of injections into the cell results in a complete protein dissociation and 
thus give the largest heat changes (Fig. 4.18 and Fig. 4.19). The following injections 
will reveal a gradual decrease in the heat-changes as the protein concentration in 
the cell approaches the midpoint (concentration of the Tetradecameric/heptameric 
rings/monomer equilibrium), toward the end of the titration, injections will not 
Figure 4.17 Thermal unfolding of Hsp60 subunits after dissociation thermally induced 
(black curve). The blue dashed curve is a fit of these data to a simple two-state unfolding 
model; while the red curve curve is a fit of these data to a simple two-state unfolding model, 
containing the irreversible step (green transition) in the thermal denaturation. 
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result in dissociation and there will only be heat changes associated with sample 
dilution. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.18 GroEL ITC profiles: Calorimetric dilution experiments for exothermic 
dissociation of tetradecamers at pH 8.0.  A) Thermogram of thermal power (µJ/sec) as a 
function of time (sec) for an ITC-dilution experiment (GroEL was loaded into the titration 
syringe at a concentration of 0.4mg/ml). B) The right panel shows the integrated injection 
heat values, obtained by integrating each peak and subtracting dilution heat. Continuous 
lines (red) correspond to interpolations of the experimental data to sigmoid functions and 
are drawn as a guide for the eye. 
Figure 4.19 Hsp60 ITC profiles: Calorimetric dilution experiments for exothermic 
dissociation of tetradecamers of p-mtHsp60 and mtHsp60, respectively on the left and on 
the right. The top panel shows thermograms of thermal power (µJ/sec) as a function of time 
(sec) for an ITC-dilution experiment (Hsp60 was loaded into the titration syringe at a 
concentration of 0.4mg/ml). While the low panel shows the integrated injection heat values, 
obtained by integrating each peak and subtracting dilution heat. 
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We made ITC Titrations measurements to probe the disassembly and the dynamic 
oligomeric equilibrium in function of protein concentration. We tried to investigate 
this dynamic equilibrium between Monomers, Heptamers and tetradecamers. The 
Bayesian information criterion (BIC) suggest as to prefer the model with the lowest 
BIC (Table 4.6). That in our study means the Tetradecamer-Heptamer-Monomer 
Dissociation (THMD), Model 3. ITC results support the hypothesis that chaperonin 
group I can exist in a dynamic equilibrium between Monomers, Heptamers and 
Tetradecamers. Moreover, the three proteins, as expected, show different stability 
in the dynamic equilibrium, as highlighted by the different dHdiss (250kJ/mol 
GroEL, 120 kJ/mol p-mtHsp60 and 80kJ/mol mtHsp60), in accordance with HPLC 
and DSC conclusions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Model Description BIC 
1 Heptamer-Monomer 
Dissociation (HMD) 
24 
2 Tetradecamer-Monomer 
Dissociation (TMD) 
34 
3 Tetradecamer-Heptamer-
Monomer Dissociation 
(THMD) 
20 
Table 4.6 BIC of different models for GroEL 
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4.3 Conclusions 
 
We investigated the (dis)assembly and thermal stability of mtHsp60, p-mtHsp60 
and GroEL in vitro, by means of DSC, ITC, HPLC and CD. Altogether, our findings 
suggest that the evolution of GroEL has generated such extreme cooperativity in 
unfolding in order to maximize its functional lifetime under harsh conditions. In 
turn, mtHsp60 is less stable than GroEL and p-mtHp60, with a lower cooperativity 
in the thermal denaturation transition and a lower ∆Hdiss. We think that the main 
biological meaning is due to a more versatility and flexibility of eukaryotic 
(particularly mtHsp60) proteins than prokaryotic, suggesting that subunit flexibility 
should be closely related to the evolutionary history of a complex. Moreover our 
results suggests that GroEL and Hsp60s exist in a dynamic equilibrium between 
monomeric/heptameric/tetradecameric rings, and that the unfolding is coupled to 
the dissociation of the oligomeric protein. We believe that these studies in vitro of 
cooperativity, structural and thermal stability, on bacterial and human Hsp60 
(across two proteins where these differences have functional relevance) could help 
to validate their role in physiological or pathological cases, and moreover for the 
development of biomolecular nanocarriers, opening new possibilities for targeted 
drug delivery.  
 
 
The major part of the results discussed in this chapter are contained and were 
presented in the following works: 
 “(DIS)Assembly and Structural Stability of mtHsp60 and its Precursor NaÏve 
Form”, by Dario Spigolon, Silvia Vilasi, Maria Rosalia Mangione, PierLuigi San 
Biagio, Donatella Bulone, presented during the Biophysical Society (Biophysical 
Society 59th Annual Meeting, Baltimore, Maryland, February 7-11, 2015) and 
published in  Biophysical Journal Volume 108, Issue 2, Supplement 1, p502a, 27 
January 2015 DOI: http://dx.doi.org/10.1016/j.bpj.2014.11.2751 
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Chapter V 
 
Hsp60, amateur chaperone in amyloid-beta fibrillogenesis 
 
 
 
5.1 Aim and introduction 
 
As was explained in chapter I, molecular chaperones are a very special protein class 
that plays essential roles in many cellular processes like folding, targeting and 
transport of proteins. In chapter II was highlighted that recent evidence indicates 
that chaperones can act as potentially strong suppressor agents in Alzheimer’s 
disease (AD). Indeed, in vitro experiments demonstrate that several chaperones are 
able to significantly slow down or suppress aggregation of A peptide and in vivo 
studies reveal that treatment with specific chaperones or their overexpression can 
ameliorate pathological behavior dysfunction of AD.  
We investigated, by a biophysical approach, the effect of the human chaperonin 
Hsp60 (at a protein concentration, as seen in paragraph 4.1, where most of the 
oligomeric equilibrium is shifted versus tetradecameric and heptameric state) on 
A fibrillogenesis. The binding between mt-Hsp60 and Aβ was evaluated, by ITC, 
at different Aβ structures, both in monomeric and in monomer/oligomer 
equilibrium forms as well as during fibrillogenesis. 
We found that Hsp60 exerts a powerful inhibiting action on A aggregation. 
Despite the homology of Hsp60 to GroEL, a folding chaperone (chapter I, 
paragraph 1.1.4), we observe that Hsp60 inhibits A through a different more 
complex mechanism. The action is specifically tooled on the early oligomeric 
species behaving as aggregation seeds for on pathway amyloid fibrillogenesis. This 
amateur mechanism has the surprising appearance of memory effect, by which if 
the A peptide species, prone for amyloid aggregation, had been once in contact 
with Hsp60, they cannot fibrillate anymore (see Fig. 5.1). 
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Figure 5.1 Simplified scheme of Aß1-40 amyloid aggregation in the absence and in the 
presence of Hsp60. The initial sample is heterogeneously formed by generically described 
on-pathway (orange) and off pathway species (dark blue) with different amyloid molecular 
fates. Under amyloid formation protocol (37°C and stirring) seeds (red full circles) able to 
catalyze the reaction form allowing the on pathway species aggregating toward amyloid 
fibrils. The remaining off-pathway species are those not able to form fibrils. In the presence 
of Hsp60, the active seeds become inactive (blue full circles) and, in this condition, neither 
off-pathway species can form fibrils anymore.  
 
 
5.2 Results & Discussion 
 
Molecular chaperones act at all the above mentioned levels we listed in paragraph 
2.1.2 (“Role of molecular chaperones in Alzheimer’s disease”) and, considering 
their functional complexity, it is hard to imagine other molecules, synthetic or 
natural, able to exert the same action with the same effectiveness. All these 
considerations strongly suggest that the pharmacological activation and induction 
of specific chaperones can be an effective therapeutic approach [5.1-5.4]. Indeed, 
these strategies are rapidly emerging as promising treatments for cancer 
intervention [5.4, 5.5], but, in the neurodegeneration field and particularly in AD, a 
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careful evaluation of potential pitfalls is necessary. In fact, Aβ oligomers are 
characterized by a very broad structural polymorphism with different epitope 
exposure, antibody-binding properties and peculiar toxicity features [5.6, 5.7]. To 
be considered for a promising therapeutic approach, chaperones should be able to 
block monomer aggregation or to favor the formation of nontoxic Aβ oligomeric 
variants. In the working mechanism of molecular chaperones, 
folding/holding/disaggregating (see chapter I), could be involved the coexistence 
of several and more complex mechanisms related to the specific nature of the 
molecular interactions between chaperone and protein aggregates. Increasing 
evidence highlights an intriguing feature of the activity of a natural molecular 
chaperone against misfolding events and associated reactions, suggesting that 
chaperones activity is not limited to sequestrate single unfolded monomers, but they 
can selectively interact with specific aggregated species [5.8, 5.9]. Moreover, in the 
chaperone mechanism of action, a crucial role is assumed by the presence of 
intrinsic disorder regions (IDRs) along the protein sequence [5.10].  IDRs are able 
to modulate specificity and affinity in protein binding. Therefore, it becomes 
fundamental to study the specific mechanisms of interaction of these chaperones 
with pathogenic amyloid-forming proteins. In this study, we analyze the effect of a 
human chaperonin Hsp60, homologous to the bacterial GroEL, on the aggregation 
process of Aβ 1-40 peptide involved in AD. As studied in the previous paragraph 
4, differently from GroEL, (that is found mainly as a tetradecameric conformation 
organized in two heptameric rings) Hsp60 seems to exists in a deeper dynamic 
heptamer/tetradecamer equilibrium [4.1, 5.11, 5.12] where monomers are found, as 
well, under certain conditions for mitochondrial Hsp60 [5.13, 5.14] (see SEC-
HPLC results in chapter 4). The major flexibility and richer functional 
conformational ensemble have evolutionary occurred at the cost of protein stability 
and unfolding cooperativity as seen in the previous chapter [4.1, 5.15]. Hsp60, in 
its naïve and mitochondrial form assumes a crucial role in several carcinogenic and 
inflammatory processes [5.16, 5.17]. Strong interactions between Hsp60 and 
amyloid precursor protein (APP) [5.18], as well as hamster prion protein PrPc 
[5.19], have been recently revealed. Moreover, it has been found by NMR 
measurements that GroEL suppresses Aß1–40 amyloid formation by interacting 
with its two hydrophobic segments Leu17-Ala21 and Ala30-Val36, key residues in 
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fibril formation [5.20]. Furthermore, GroEL inhibits the formation of toxic alpha-
synuclein aggregates and it is capable of inhibiting the fibrillization of other 
amyloidogenic proteins such as 2 microglobulin [5.21]. 
In this chapter we show for the first time that human Hsp60, even in the absence of 
its cochaperonin Hsp10 and ATP, binds Aβ1-40 peptide and inhibits the 
fibrillogenesis of Aβ1-40 peptide leaving the peptide in an unordered conformation. 
We suggest a possible mechanism underlying this inhibitory action that could 
constitute a basic building block in the research field of therapies based on human 
molecular chaperones for AD and other neurodegenerative diseases. 
 
 
 
 
ITC Measures: Binding Aβ/mtHsp60 
ITC measurements were performed to investigate the chaperone effect and 
mechanism on Aβ aggregation process. The binding between mt-Hsp60 and Aβ was 
evaluated at different Aβ structures, both in monomeric and in monomer/oligomer 
equilibrium forms as well as during fibrillogenesis.  
The observed binding isotherms were ﬁtted to the “one set of sites” model (see 
material and methods). In this model, the putative chaperonin has several identical 
substrate binding sites, which are independent of each other and have a uniform 
binding constant, Ka, and enthalpy change, ∆H. The best fitting parameter values 
are listed in Table 5.1. The binding curves are shown in Fig. 5.2. 
 
Table 5.1 Binding parameter for aβ and mtHsp60 
 
 
Titrant in mtHsp60 
 (50 µM) 
 
n kd  
(M) 
∆Hd 
(kJ/mol) 
Ka 
 (M-1) 
∆Sd 
(kJ/mol K) 
aβ monomer/mtHsp60 3.9 3.30*10-8 -13.23 3*107 98.84 
aβ oligomer/mtHsp60 4.1 3.04*10-6 -27.82 3.3*105 12.29 
aβ fibers/mtHsp60 n.a n.a n.a n.a n.a 
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The theoretical curves (solid red lines) show a good match with the experimental 
data (squares) at different Aβ structures, both in monomeric and in 
monomer/oligomer equilibrium forms as well as during fibrillogenesis. No binding 
occurs between aβ fibers and mtHsp60, while mtHsp60 shows up more affinity in 
the binding with aβ monomer, as highlighted by the lowest Kd (3.30*10-8 M), than 
aβ oligomer (3.0410-6 M).  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
Effect of mtHsp60 on Aβ1-40 amyloid aggregation process 
In order to investigate the direct effect of Hsp60 on Aβ1-40 amyloid aggregation 
process, different experimental techniques were used to investigate the evolution of 
the structural organization of aggregates formed in the presence and in the absence 
of Hsp60 under pro-aggregating conditions, i.e. stirring and 37 °C [5.22, 5.23].  
ThT fluorescence assay, a widely accepted method to reveal β-sheet formation 
preliminary to the fibrillation process, was applied. Figure 5.3 shows a quick and 
sharp increase in ThT emission intensity for Aβ sample that indicates the 
Figure 5.2 ITC Binding curves: Hsp60/Aβ at different structures; red spot are the 
monomer, blue ones are the oligomers and black ones are the fibers. 
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appearance of cross-β-structure. On the contrary, no significant change of ThT 
fluorescence can be observed for Aβ1-40 sample treated with Hsp60 an up to 24 
hours, suggesting that the amyloid fibrillation is inhibited by chaperone presence. 
Coherently, at the end of the kinetics, the secondary structural conversion that 
accompanies amyloid formation for Aβ peptide is not observed in the presence of 
the chaperonin (Fig. 5.3B) and no fibrils are observed by AFM (Fig. 5.4).  
Figure 5.3B shows the dichroic spectra of Aβ1-40 samples in presence or in absence 
of the chaperonin, recorded at the initial time and after 24 hrs from the beginning 
of the process. The CD spectra show a typical evolution of Aβ1-40 peptide from 
random coil to β-sheet structure. On the other hand, the sample incubated with 
Hsp60 retains a typical random coil profile until the end of kinetics. Therefore, CD 
experiments agree with ThT assays confirm that Hsp60 exercises an inhibitory role 
on the onset of Aβ1-40 beta structure formation that typically accompanies the 
peptide assembly toward more ordered structures. Other details on the structural 
organization of these samples were obtained by AFM imaging. ure 5.4 shows 
images acquired at initial and final state for both samples, incubated with or without 
Hsp60. Noteworthy, the fibrillation is evident for sample of Aβ1-40 alone, whereas 
the peptide treated with Hsp60 does not show fibers, neither significant differences 
between the initial and the final step of the kinetics. 
 
 
 
 
 
 
 
 
Figure 5.3 On the left (panel A): Influence of Hsp60 on A aggregation kinetics. 
Kinetics of 50 µM Aβ (black line) and 50 µM Aβ + 2 µM Hsp60 (red line) monitored by 
ThT fluorescence assay. Condition: T = 37°C stirring 200 rpm ThT 12 µM. On the right 
(panel B): Influence of Hsp60 on A aggregation secondary structure variations 
during fibrillogenesis. CD spectra recorded at 20 °C for 50 µM A1-40 at initial time (black 
line) and after 24 hrs at 37°C and 200 rpm (black dotted line), compared with spectra for 
sample with 2 µM Hsp60 at the at initial time (red line) and after 24 hrs at 37°C and 200 
rpm (red dotted line). The CD contribute of Hsp60 was subtracted to a better comparison.  
A B 
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Molecular mechanism of HSP60 
Different hypotheses about possible molecular mechanisms of Hsp60 could be 
formulated to explain the phenomena observed. One of these, considering the 
absence of ATP, would attribute to Hsp60 a “holding” role. Hsp60 could act as a 
non-catalytic inhibitor of polypeptide aggregation, by sequestering single unfolded 
conformations of monomers [5.10]. SEC experiments helped us getting light on this 
hypothesis. 
Hydrodynamic size and oligomeric organization of Aβ1-40 samples incubated for 
24 hrs with or without HSP60 were analyzed by SEC using a Superdex 200 increase 
column. The chromatographic profiles, registered at 280 nm, are shown in figure 
5.5 and compared with the Aβ chromatographic profile registered at the initial state 
of the aggregation kinetics. The early part of the chromatogram (7-10 min) accounts 
for Hsp60 in tetradecameric and heptameric structures. Hsp60 monomers and its 
Figure 5.4 Morphology of Aβ species formed in the presence of Hsp60 under amyloid 
aggregation conditions. AFM images acquired for: 50 µM Aβ  at the at initial time (a) and after 
24 hrs incubation at 37 °C and 200 rpm (b) compared with 50 µM Aβ 1-40  incubated with 2 µM 
Hsp60 at the initial time (c) and after 24 hrs of incubation at 37 °C and 200 rpm (d). Scale bars: 
1 µm, Z-range: (a, b, c) 7 nm; (d) 9.6 nm. 
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fragments fall in the region of the chromatogram between 10 and 14 min (as seen 
in chapter 4.1). Finally, Aβ1-40 peptide peak is observed in the region between 16 
and 18 minutes. The Aβ chromatographic area is notably lower for the sample 
incubated at 37°C for 24 hrs (blue curve in the last part of the chromatogram where 
Aβ1-40 elutes). The missing sample is the component of the Aβ peptide sample 
predestined for forming amyloid on pathway large prefibrillar structures and mature 
fibers, evidenced by AFM experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After incubation at 37 °C under stirring, Aβ sample, as a consequence of fibril 
formation, presents a significant reduction in the low size oligomeric peak (70% of 
the initial sample) (see scheme reported in Fig. 5.1).  
The residual part of this peak, not involved in amyloid aggregation, is formed by 
off-pathway species that, when incubated again under amyloid formation 
conditions, result only able to form very low amounts of amyloid fibrils. In the 
presence of Hsp60 under the same conditions, no large difference in the 
chromatographic profile is noticeable in the Aβ sample other than peaks 
corresponding to chaperone oligomers. In particular, the low size oligomeric peak 
seems to be almost unvaried, with respect to the freshly dissolved Aβ sample. This 
means that also the fraction of Aβ molecules that in the absence of Hsp60 would be 
involved in amyloid fibrils formation, in the presence of the chaperonin is 
Figure 5.5 Investigation on the influence of Hsp60 on oligomeric distribution of A after 
incubation under amyloid aggregation conditions. Analytical chromatographic profiles 
recorded at 280 nm for 50 µM A1-40 freshly dissolved (black line) and after 24 hrs of 
incubation at 37°C and 200 rpm with or without 2 µM Hsp60, red line and blue line 
respectively. The column was calibrated using globular protein standards. 
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unaffected both in hydrodynamic size and amount with respect to the freshly 
dissolved sample. The Aβ molecules normally involved in the aggregation pathway 
leading to fibers are no longer recruited in presence of Hsp60. Moreover, this 
evidence strongly excludes the possibility that the molecular chaperone sequesters 
the total Aβ sample, or a substantial part of it, by exerting a global holding action 
on Aβ molecules.  
These results lead naturally to the hypothesis that Hsp60, following its 
professional activity but in the absence of ATP, induces a conformational change 
in Aβ peptide that irreversibly impair any further aggregation. Differently from 
GroEL, whose chaperone molecular actions are widely studied and known to 
involve cochaperonin GroES and ATP in an allosteric communication between the 
two heptameric rings [5.24, 5.25], functional mechanisms of the mitochondrial 
human homologue Hsp60 are very poorly investigated.  
Differences in the key residues involved in the double rings formations reflect 
the existence of a dynamic equilibrium in solution between monomers, heptamers 
and tetradecamers conformations [4.1, 5.11, 5.14, and 5.26]. Indeed a single ring 
seems to be sufficient for folding assistance in vivo [5.26], even though potential 
mechanisms involving the interaction with co-chaperonins should be further 
clarified. For sure, similarly to GroEL, the apical domain of Hsp60 contains 
hydrophobic residues that could be the most involved in the misfolded proteins 
recruitment [5.27]. However, our data exclude any active influence of Hsp60 
influence on Aβ folding, either monomers or low size oligomers present in the 
sample after the preparation protocol but before incubation with the chaperone. In 
fact, no variation in amyloid aggregation behavior is detectable in Aβ sample 
isolated after incubation with the chaperone under not destabilizing conditions (4 
°C without stirring) [results shown in the article “Hsp60, amateur chaperone in 
amyloid-beta fibrillogenesis”, Mangione MR, Vilasi S, Marino C, Librizzi F, 
Canale C, Spigolon Dario, Bucchieri F, Fucarino A, Passantino R, Cappello F, 
Bulone D, San Biagio PL, published in  Biochimica et Biophysica Acta (BBA) 2016 
Jul 26. pii: S0304-4165(16)30266-5]. 
The only acceptable conclusion is that Hsp60 might act selectively on the specific 
Aβ amyloid species activated by simultaneous stirring and temperature increase, or 
by preventing their formation, or, as more probable, by inhibiting their activity by 
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a folding or a holding action (see scheme reported in Fig.5.1). These seeds although 
very low in number, have the proper molecular determinants to constitute 
productive steps in the fibrillation pathway and to determine the behavior and 
amyloid aggregation in the highest fraction of the whole Aβ population [5.28].  
It is well known in fact that a given protein can self assemble into various 
aggregated forms, depending on the peculiarities of its environment. The presence 
of active seeds, paves the way, among the heterogeneous routes leading to the 
various aggregated forms, of the amyloid on pathway fibrillization [5.28]. In the 
presence of Hsp60, the recruitment or inactivation of these catalytic seeds close the 
route of on pathway amyloid fibrillogenesis. 
Actually, as recently shown, a strong inhibition of aggregation can be observed, 
even at extremely low doses of inhibitors, for systems such the Aβ peptide, where 
secondary nucleation mechanisms play a key role. In fact, in these cases, the whole 
aggregation process can be prevented by the sequestration of small amounts of 
aggregates, before that these seeds can trigger the autocatalytic proliferation of 
aggregates brought about by secondary nucleation, as will be investigated in the 
chapter 7  [5.8, 5.9, 5.29, 5.30]. This shows an intriguing feature recently proposed 
for the activity of a natural molecular chaperone against misfolding events and 
associated reactions, indicating that the roles of chaperones are not limited to the 
sequestration of single monomeric unfolded conformations, but can involve 
multiple interactions with aggregated species [5.8, 5.9]. Our hypothesis is that the 
chaperone selectively exerts a selective action against the Aβ aggregated species 
that specifically form during on pathway aggregation under environmental stress 
conditions, probably by means of interactions involving peculiar hydrophobicity 
and exposure to the solvent properties of these Aβ aggregates conformations. These 
prion-like Aβ conformations could represent novel targets for interrupting the 
spread of Aβ deposition in AD patients [5.31]. 
 
 
5.3 Conclusions 
 
Our results confirm the extraordinary potentiality of molecular chaperones in 
interfering with the crucial molecular steps leading to amyloid aggregation in 
neurodegeneration and demonstrate that Hsp60 is able to target the Aβ species 
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responsible for induction of amyloid protein assembly. Although, the specific 
mechanisms by which the presence of the chaperone neutralize these types of Aβ 
protein aggregates, preventing their formation or inhibiting them, remain to be 
elucidated. Due to the high grade of flexibility of the protein structure, chaperones 
can interact with a very wide spectrum of biological molecules and protein 
conformations and with a high versatility of mechanisms of action [5.10], exploiting 
as in the case of Hsp60 and Aβ oligomers, amateur, non-classical mechanisms 
[5.32]. In the absence of active seeds, and in the only presence of off-pathway 
species, also the highly prone to aggregate Aβ peptide becomes unable to form new 
seeds and subsequently to fibrillate. 
In the last few years, chaperones appear to be an emerging and hopeful therapeutic 
strategy for the neurodegeneration field. In this respect, we believe that the 
investigation on the biophysical features of the interactions between specific 
chaperones and the specific protein structures involved in disease is a crucial basic 
step towards the development of effective chaperones-based approaches. 
  
 
 
 
 
 
 
 
 
The major part of the results discussed in this chapter are contained in the paper:  
“Hsp60, amateur chaperone in amyloid-beta fibrillogenesis”, by Mangione MR, 
Vilasi S, Marino C, Librizzi F, Canale C, Spigolon Dario, Bucchieri F, Fucarino 
A, Passantino R, Cappello F, Bulone D, San Biagio PL, published in  Biochimica 
et Biophysica Acta (BBA) 2016 Jul 26. pii: S0304-4165(16)30266-5. doi: 
10.1016/j.bbagen.2016.07.019.  
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Chapter VI 
 
Diseases caused by defective molecular chaperones: Quantitative 
analysis of the impact of a pathogenic mutation on the CCT5 
chaperonin subunit using a proxy archaeal ortholog (Dis)assembly 
and Structural Stability 
 
 
 
6.1 Aim and introduction 
 
Defects in protein folding and other abnormalities, many associated with 
chaperonopathies, are typical of a wide variety of human diseases, including 
chronic inflammatory and autoimmune conditions, cancer, and amyloid diseases 
such as Huntington’s, Parkinson’s, and Alzheimer’s diseases [6.14, 6.15].  
However, the elucidation of the structure-function relationship of pathogenic 
chaperones remains challenging due to the complexity of the chaperoning multi-
molecular machines typical of humans and even of simpler eukaryotes. Recently, a 
protein model has been proposed for investigating the functionality of a Group II 
chaperonin: the eukaryotic CCT (chaperonin containing TCP1), also called TRiC 
(TCP1-ring complex) [6.1-6.3]. CCT is an obligate chaperone for at least 10% of 
eukaryotic proteomes [6.4]. Several chaperonopathies linked to CCT loci are 
clinically well characterized and, for those due to non-lethal genetic mutations, 
there is considerable information on their mode of inheritance [6.5]. The Group II 
chaperonins such as CCT, which are universally found in Archaea and eukaryotes, 
feature a built-in lid that opens and closes over a central chamber. In eukaryotes in 
general, the chaperonin CCT is hetero-oligomeric, consisting in humans of two 
stacked rings of eight non-identical but similar subunits per ring. CCT is required 
for folding and stabilization of various essential proteins such as actin, tubulin, and 
cell-cycle regulators in humans and other organisms [6.6-6.11]. In addition, CCT 
modulates and suppresses the aggregation of neurologically toxic proteins with 
polyglutamine motifs [6.12-6.15]. The CCT conformation induced by ATP 
hydrolysis is closely associated with the productive folding of the substrate [6.16].  
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The protein model recently developed was aimed to address the mechanism of a 
crippling hereditary sensory neuropathy which is the result of a point mutation 
(His147Arg) in CCT5, one of the eight subunits of the human CCT [6.18, 6.19]. 
The critical mutation identified in patients suffering from this progressive condition 
was introduced into the ortholog chaperonin encoded by a hyperthermophilic 
marine archaeon, Pyrococcus furiosus, which shares 44% sequence identity with 
the human CCT5 [6.17, 6.20]. In the disease model, each of the 8 archaeal subunits 
in the two identical octamers that build the chaperoning hexadecamer carries the 
mutation. Therefore, the impact of the mutation is multiplied eight-fold per ring 
compared to the human CCT octamer. This amplification has proved instrumental 
for detecting subtle effects of a mutation, such as those which are likely to occur in 
humans, namely mutations that cause pathology but are compatible with survival. 
Indeed, the authors (Min et al., 2014) observed a decreased stability and impaired 
chaperoning function in the hexadecamer formed by the mutant subunit. In this 
work, we use differential scanning calorimetry (DSC), isothermal titration 
calorimetry (ITC), high performance liquid chromatography (HPLC), static light 
scattering (SLS) and circular dichroism (CD) to obtain quantitative information on 
the loss of structural stability in the hexadecamer containing the pathogenic 
mutation. 
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6.2 Results & Discussion 
 
Thermal Unfolding 
 
 
DSC experiments were carried out to gain quantitative information on the 
thermodynamic parameters controlling the protein stability.  Fig. 6.1 shows the 
thermal profiles for Pf-CD1, Pf-H and Pf-R obtained at 60 °C/h scan rate and 7μM 
concentration. For all three proteins, we observed a biphasic melting that could be 
reasonably attributed to dissociation of the molecular complex followed by 
monomers unfolding.  The asymmetry observed in the DSC thermograms is evident 
for all three proteins (particularly for Pf-H and Pf-R), and all peaks are skewed at 
temperatures below the transition midpoint (Tm), where the transition is less sharp 
and deviates more from the two-state fit, as expected for a transition coupled to 
dissociation [6.21, 6.22]. Overall, the three proteins showed a considerable 
difference in structural stability, as demonstrated by the strong difference in 
calorimetric enthalpy (182 kcal/mol for Pf-R, versus 308 and 515 kcal/mol, for Pf-
H and Pf-CD1, respectively, Table 6.1). In particular, the pathogenic mutant Pf-R 
is the least able to maintain the complex structure with increasing temperature, 
whereas Pf-CD1 is the most stable. 
 
 
Figure 6.1 Differential scanning calorimetry thermograms for Pf-CD1 (red), Pf-H 
(green), and Pf-R (blue), at 7 μM concentration. The scan rate was 60 °C/h.  Calorimetric 
traces are given after subtraction of the instrumental base line. All the three proteins show 
biphasic melting that is interpreted in terms of hexadecamer disassembly followed by 
monomers denaturation (see text).  For Pf-CD1, the two transitions are closer coupled. 
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Pf-CD1 showed more stability with respect to Pf-H and Pf-R and the highest ability 
to maintain the complex structure. Moreover, the asymmetry observed in the DSC 
thermograms is evident for all proteins (particularly for Pf-H and Pf-R), and all 
peaks are skewed at temperatures below the transition midpoint (Tm), where the 
transition is less sharp and deviates more from the two-state fit, as expected for a 
transition coupled to dissociation [6.21-6.24].  
 
 
 
 
 
 
Table 6.1. Thermodynamic parameters for heat denaturation 
 
Proteina Tm  
(°C) 
∆Hcalb  
(kcal/mol) 
∆Hvh  
(kcal/mol) 
Rc 
Pf-CD1 102.6 515 214.2 2.4 
Pf-H 103.2 308 197.2 1.56 
Pf-R 102.7 182 160.3 1.14 
 
a7 μM 
 
b∆Hcal and ∆Hvh per subunit 
 
cR=∆Hcal/∆Hvh 
 
 
 
 
 
To investigate the nature of the double peak in the thermogram, we did DSC 
experiments at varying protein concentration. Indeed, a decrease of the total molar 
calorimetric enthalpy should be observed if the unfolding is coupled to dissociation 
of oligomeric complexes. Results in Fig. 6.2 clearly illustrate that amplitude of the 
lower temperature peak decreases with decreasing protein concentration, while the 
higher temperature peak remains unchanged, thus validating the hypothesis of 
unfolding coupled to oligomers dissociation. 
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Figure 6.2 Differential scanning calorimetry at different protein concentrations. For 
each protein, the concentrations were 7 μM (red), 3.5 μM (blue), and 1.7 μM (black). Panels 
A, B, C are the thermograms for Pf-CD1, Pf-H, and Pf-R, respectively. Panels A1, B1 and 
C1 are the variations in total measured enthalpy as a function of concentration.  
 
 
The presence of oligomers and the relative molecular weight distribution in native 
and unfolded proteins was investigated by HPLC measurements. Results in Fig. 6.3 
evidence that all three proteins in the native state are mainly assembled in octamers 
and hexadecamers  with some fraction of dimers and monomers., The total area of 
chromatogram for each protein after unfolding is strongly reduced, as probably due 
to formation of aggregates that do not enter in the column. The largest effect is 
found for Pf-R (72%). For Pf-H and Pf-CD1, the reduction is 50 and 26%, 
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respectively. In addition, the unfolded proteins display a different oligomeric size 
distribution as they appear enriched in dimers and monomers. This indicates that 
most of the thermal denatured transition is from the oligomeric dissociation. The 
largest change is observed for Pf-R, which becomes richer in monomer and dimer, 
compared with the other proteins.  Thus, the mutation appears to impact the 
oligomer's thermodynamic stability and its ability for effective self-organization in 
vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Analysis of oligomer components by size-exclusion chromatography. A280 
traces collected from samples of Pf-CD1, Pf-H and Pf-R, before (continuous lines) and 
after (dashed lines) thermal denaturation are shown all together in the top panel and divided 
by protein in the panels A, B, C. Non-denatured samples comprise four species (labels 
above peaks). After denaturation, some fraction of hexadecamer reforms while the octamer 
species is generally absent. After heating, Pf-R is richer in monomer and dimer, compared 
with the other proteins. For each protein, the total area of chromatogram is reduced after 
denaturation, as probably due to formation of aggregates that do not enter in the column. 
The largest effect is found for Pf-R (72%). For Pf-H and Pf-CD1, the reduction is 50 and 
26%, respectively. 
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Results from Circular Dichroism measurements on native and thermally unfolded 
proteins, reported in Fig. 6.4, show that oligomeric dissociation is associated to a 
mild conformational change.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Circular dichroism. CD spectra for Pf-CDl (panel A), Pf-H (panel B), 
and Pf-R (panel C) before (cred, green and blue lines) and after (magenta lines) thermal 
denaturation. All samples show a predominance of alpha helical structure (maxima near 
190 nm and minima near 210 and 225nm), which is slightly reduced in unfolded 
samples. Secondary structure composition and assignments from CD spectra are given 
in Table 6.2. 
 
 
 
Table 6.2 Secondary structure composition and assignments from CD spectra for 
native and unfolded protein 
 
Protein Alpha-Helixa Beta-Sheet Turn Random Coil 
Pf-CD1 native 50 12 12 26 
Pf-CD1 unfolded 41 23 10 26 
Pf-H native 49 21 10 20 
Pf-H unfolded 40 24 10 26 
Pf-R native 50 21 9 20 
Pf-R unfolded 44 20 8 27 
 
aPercent of alpha-helix, beta-sheet, turn and random coil structure obtained by CDPro 
analysis of CD spectra [6.30]. 
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Effect of mutation on the structural stability 
 
The oligomeric equilibrium of the three chaperonins as a function of protein 
concentration was investigated by ITC measurements at room temperature. The 
protein solutions were loaded into the titration syringe at a concentration of 0.3 
mg/mL. Each titration consisted of 18-19 successive injections of 5 µL protein 
solution into the reaction cell (980 µL) filled with buffer only. Results are shown in 
Fig. 6.5, panels A and B. ITC curves were analysed by using a hexadecamer-
monomer equilibrium model.   
The equilibrium constant and mass balance equations are in this case: 
 
 𝑀16 ↔ 16𝑀 
𝐾𝑑 =
[𝑀]16
[𝑀16]
 
[𝑀]𝑡 = [𝑀]
 +  16[𝑀16] 
16
[𝑀]16
𝐾𝑑
+ [𝑀] − [𝑀]𝑡 = 0 
Here Kd is the dissociation equilibrium constant, [M] and [M16] are the equilibrium 
concentrations of the monomer and hexadecamer, respectively, and [M]t is the total 
monomer concentration. The total concentration of protein (in a monomer base) in 
the calorimetric cell after each injection i can be calculated as: 
[𝑀]𝑡,𝑖 = 𝑃0 (1 − (1 −
𝑣𝑖𝑛𝑗
𝑉0
)
𝑖
) 
The free monomer concentration after each injection i, [M]i, can be calculated by 
using the previous equations, and the normalized heat associated with each 
injection, Qi, is given by: 
𝑄𝑖 =
𝑉0∆𝐻𝑑
𝑣𝑖𝑛𝑗𝑃0
([𝑀]𝑖 − [𝑀]𝑖−1 (1 −
𝑣𝑖𝑛𝑗
𝑉0
) − 𝐹0𝑃0
𝑣𝑖𝑛𝑗
𝑉0
) + 𝑞𝑑 
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Where ∆Hd is the enthalpy change due to dissociation, Vo is the reaction volume, 
vinj the injected volume, Po is the molar concentration in the syringe, and F0 is the 
fraction of monomers in the syringe.  
The hexadecamer-monomer model reproduces reasonably well the experimental 
data, and there is no need for considering intermediate states. According to this 
model, the oligomeric equilibrium of the three chaperonins can be studied as a 
function of concentration, by revealing the fractions of monomers and oligomers in 
the cell after each injection. The heat released or absorbed in each injection will be 
proportional to the increment of monomer concentration .The presence of 
monomers at high protein concentration, especially for Pf-R, was confirmed by 
native 4-9% gradient native-PAGE analysis ([6.17]) and by HPLC (see Fig. 6.3). 
The oligomer's dissociation constants Kd, along with ∆Hd and other thermodynamic 
parameters calculated for the oligomeric equilibria of Pf-CD1, Pf-H and Pf-R are 
summarized in Table 6.3. The assembly of the hexadecameric complex is 
endothermic and entropically driven. Moreover, the negative Gibbs free energy 
indicates that, for all the three proteins, disassembly is a thermodynamically 
favorable reaction as long as the concentration is lower than the critical transition 
concentration (CTC). 
The overall enthalpy change may include three different contributing factors: (i) 
Interaction enthalpy between subunits (∆Hi); (ii) Conformational enthalpy of 
subunits (∆Hc); and (iii) Solvation enthalpy of subunits (∆Hs) [6.25]. ∆Hi 
corresponds to the enthalpy changes from non-covalent interactions such as 
hydrogen bonding, electrostatic forces, and van der Waals interactions. ∆Hs 
represents the enthalpy due to the uptake or release of the ordered water molecules 
from the contact interface (hydration-dehydration phenomena), and ∆Hc is related 
to the conformational enthalpy when an ordered secondary/tertiary/quaternary 
structure of the protein is formed. Considering the unfavorable positive enthalpy 
value of Pf-CD1 assembly and the large negative dissociation enthalpy, it may be 
concluded that ∆Hc + ∆Hi values are exothermic.  Consequently, oligomer 
dissociation with negative enthalpy implies that the aggregation process is 
endothermic and entropically driven [6.26].  The total endothermic enthalpy of 
monomer binding is attributed to a large unfavorable, positive solvation enthalpy 
due to the release of ordered water molecules from the monomer-oligomer 
 
 
 Dario Spigolon 
 
95 Biophysical investigation on therapeutic proteins (Chaperonins, Hsp60 and CCT/TRiC) involved in human diseases 
interface. Protein folding and ligand binding to proteins through hydrophobic 
interactions are often accompanied by the burial of nonpolar surfaces from water 
[6.27]. The positive entropy associated with Pf-proteins assembly follows the 
classical hydrophobic effect, which is an entropy-driven process. Partitioning of a 
nonpolar molecule from water to a nonpolar phase is accompanied by an increase 
in the entropy of the system. Since the Pf-protein interfaces are mostly hydrophobic, 
there may be a large number of ordered waters released upon assembly. Thus, both 
the favorable entropy and the unfavorable enthalpy can be explained by a release 
of ordered water molecules upon hexadecamer assembly, especially in the case of 
Pf-CD1, where the hydrophobicity is higher than for Pf-H and Pf-R. 
 
Figure 6.5 Isothermal titration calorimetry of the oligomer assembly process for Pf- 
CD 1 (red), Pf-H (green), and Pf-R (blue). Panel A shows the measured heat for 18 
successive injections and best fit to a two-state curve according to a hexadecamer-monomer 
equilibrium. Panel B shows the corresponding normalized molar heat functions. Pf-R 
remains assembled in hexadecamers at lower concentration, but with a smaller energy of 
assembly. 
 
 
 
Table 6.3. Thermodynamic parameters for the hexadecamer-monomer equilibriaa  
 
Protein kd (μM) ∆Gd  
(kcal/mol) 
∆Sd 
(kcal/mol K) 
∆Hd 
(kcal/mol) 
Pf-CD1 0.31 ± 0.06 -8.8 ± 0.1 -1.14 ± 0.01 -350 ± 5 
Pf-H 0.43 ± 0.05 -8.7 ± 0.24 -0.81 ± 0.02 -250 ± 7 
Pf-R 0.1 ± 0.05 -9.5 ± 0.3 -0.13 ± 0.04 -49 ± 1.7 
aAll parameters are expressed per subunit. 
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Effect of mutation on protein function 
 
ATP binding was investigated by ITC, Fig. 6.6, panels A, B, C. All three proteins 
bind ATP, but with different binding mechanisms. The binding isotherms best fit 
was in terms of a model considering several identical and independent binding sites 
(described in chapter III). In this model, the chaperonin has 16 identical nucleotide 
binding sites, which are independent of each other and have a uniform binding 
constant, Ka, and enthalpy change, ∆H. The best fitting parameter values are listed 
in Table 6.4. The theoretical curves showed a good match with the experimental 
data for ATP. The three proteins showed different ATP-binding mechanisms: in 
particular, Pf-R shows an exothermic binding enthalpy ∆H (-26.8 kcal/mol) 
compared to the endothermic ones of Pf-CD and Pf-H (4.3 and 6.5 kcal/mol, 
respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Isothermal titration calorimetry for ATP binding to the chaperonins: Pf-
CD1 (A), Pf-H (B), Pf-R(C). The enthalpies of ATP binding are reported as a function of 
ATP stoichiometry. The best-fit curves are based on a model that assumes a single binding 
site per subunit. Note that a molar ratio of 16 corresponds to one ATP per subunit. 
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Table 6.4. ATP-binding parameters obtained by the “one set of sites” modela 
 
Protein n kd  (μM) ∆S (cal/mol K) ∆H (kcal/mol) 
Pf-CD1 12 ± 3 0.21 ± 0.05 44.4 ± 9.5 4.3 ± 1.4 
Pf-H 16 ± 1.2 0.2 ± 0.02 51.8 ± 5.8 6.5 ± 0.8 
Pf-R 29 ± 0.6 0.38 ±0.01 -57.2 ±3.2 -26.8 ± 0.85 
 
aAll parameters are expressed per hexadecamer. 
 
 
 
The effect of ATP binding on protein conformation were investigated by DSC 
experiments. Thermograms for the three proteins in the presence of ATP are shown 
in Fig. 6.7. The comparison between the thermodynamic parameters for unfolding 
in the absence (Tab. 6.1) and ATP presence (Tab. 6.5) indicates that for both Pf-H 
and Pf-R bounded to ATP the unfolding takes place at lower temperature, whereas 
little change is observed for Pf-CD1.  The total enthalpy cost for unfolding in ATP 
presence is increased for Pf-H and decreased for both Pf-CD1 and Pf-H. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 ATP effect on DSC thermograms for Pf-CD1 (A), Pf-H (B) and Pf-R (C). 
Colored proﬁles are relative to the proteins in absence of ATP. The black line in each panel 
is the thermogram recorded in the presence of 0.015 mM ATP. 
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Table 6.5. Thermodynamic parameters for heat denaturation in the presence of 
nucleotide 
Proteina Tm 
(°C) 
∆Hcalb  
(kcal/mol) 
∆Hvh  
(kcal/mol) 
Rc 
Pf-CD1-Mg-ATP 102.5 365 239 1.52 
Pf-H-Mg-ATP 99.6 518 156 3.3 
Pf-R-Mg-ATP 99.7 157 200 0.8 
 
a7 μM 
b∆Hcal and ∆Hvh per subunit 
cR=∆Hcal/∆Hvh 
 
 
CD spectra of the three proteins in their denatured state in the presence of ATP were 
recorded at 260 to 190 nm to observe the effect of nucleotide on the secondary 
structure. Percent of alpha-helix, beta-sheet, turn and random coil structure as 
obtained by CDPro analysis are reported in supplementary data A.2. The results 
showed that the three chaperonins undergo conformational changes upon ATP 
binding. Pf-CD1 and Pf-H became more structured upon ATP binding, while Pf-R 
lost structure and resembled to more closely the denatured state. 
Overall, our results indicate that only the nucleotide endothermic binding to Pf-H, 
and to Pf-CD1, leads to conformational changes induced by Mg-ATP, showing the 
transition of the complex to the closed conformation, which is usually required for 
ATP hydrolysis to bring the lid helices into close proximity during the 
conformational cycling (conformational changes in CCT have also been observed 
by electron microscopy [6.28]. Opening of the lid occurs in conjunction with 
releasing ADP from the active site. The complex can exist in an asymmetrical 
conformation with one ring closed and one open, even during ATP cycling 
conditions, suggesting an inter-ring allosteric model mediated through a two-stroke 
mechanism [6.29]. However, the allosteric communication that occurs between the 
rings is not well understood. 
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6.3 Conclusions 
 
In conclusion, the three chaperonin molecules tested have distinct thermodynamic 
profiles, showing different disassembly behavior and implying different 
cooperativity levels and different conformational trajectories. The pathogenic R 
mutant (Pf-R) is energetically the weakest at maintaining the oligomeric complex 
and displays a distinct oligomeric equilibrium characterized by the lowest enthalpy 
of dissociation (∆Hd). Thus, the pathogenic mutation appears to reduce the protein's 
stability and its capacity for self-organization. The observed differences in ATP 
binding provide further evidence that the R mutation in Pf-R disrupts the 
chaperonin's functional cycle by failing to induce the normal conformational 
changes. Pf-R has an exothermic ∆H (-26.8 kcal/mol) compared to the endothermic 
values for Pf-CD1 and Pf-H (4.3 and 6.5 kcal/mol, respectively). This suggests that 
the pathology follows from a failure of ATP binding to induce the oligomer's closed 
conformation, which is required for ATP hydrolysis and the subsequent 
conformational cycling that underlies normal chaperonin function. 
 
 
 
 
 
 
 
 
The major part of the results discussed in this chapter are contained in the following 
paper submitted: 
 “Diseases caused by defective molecular chaperones: Quantitative analysis of the 
impact of a pathogenic mutation on the CCT5 chaperonin subunit using a proxy 
archaeal ortholog”, by Dario Spigolon, Travis Gallagher, Adrian Velazquez-
Campoy, Donatella Bulone, Jatin Narang, Pier Luigi San Biagio, Francesco 
Cappello, MD Alberto J Macario, MD, Everly Conway de Macario, Frank T Robb, 
recently submitted to Biochemical and Biophysical Research Communications.  
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Chapter VII 
Caseins: α‑Casein Inhibits Insulin Amyloid Formation by 
Preventing the Onset of Secondary Nucleation Processes 
 
 
 
7.1 Aim and introduction 
 
Our main goal was to study if an eﬃcient inhibition of amyloid formation can be 
achieved by chaperone-like systems, α-Caseins, which are able to exert a stabilizing 
function through direct interaction, and to evaluate the mechanism of chaperone-
like activity against aggregation,. For α-Casein the stabilization of partially 
unfolded ‘target’ proteins takes place through direct interactions similar to those 
induced by small heat-shock proteins (sHsps) (see paragraph 1.5). Investigation on 
its interaction mechanism could help to better understand the structural basis of the 
substrate binding in sHsps. 
As explained before, α-Casein is able to inhibit the aggregation of several proteins, 
including the amyloid ß-peptide, by mechanisms that are not yet completely clear.  
We studied the chaperone-like systems eﬀects on insulin1, a system extensively 
used to investigate the properties of amyloids (many of which are common to all 
proteins and peptides, so that it seems appropriate to talk about an "amyloid state" 
for proteins, characterized by the formation of fibrillar β-sheet rich aggregates). 
Insulin fibrillization process is characterized by a prolonged lag-phase, in which 
nothing apparently happens, followed by a sudden, explosive, growth of aggregates 
[7.1- 7.7]. This phenomenology is the fingerprint of an extremely autocatalytic 
process, brought about by secondary nucleation mechanisms, such as branching, 
heterogeneous nucleation, fragmentation, i.e. all those processes which can 
exponentially increase the number of aggregation sites [7.8]. 
 
 
 
151 residue protein hormone with a molecular weight of ~5800 Da. 
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Furthermore, in some conditions, insulin is also able to form relatively small, 
amyloid-like, oligomers, whose formation does not show any relevant lag-phase 
and which have been suggested to be off-pathway with respect to standard insulin 
amyloid fibrillation [7.9, 7.10]. 
Therefore, we have here the possibility to investigate the hindering effects of α-cas 
on different aggregation pathways of the same protein giving useful information 
both on the basic mechanisms of amyloid formation and on the strategies for its 
inhibition.  
We found that α-casein strongly delays amyloid formation, when the aggregation 
process is characterized by secondary nucleation. At diﬀerence, it has a vanishing 
inhibitory eﬀect on the initial oligomer formation, which is observed at high 
concentration and does not involve any secondary nucleation pathway. These 
results indicate that an eﬃcient inhibition of amyloid formation can be achieved by 
chaperone-like systems (see paragraph 1.5), by sequestering the early aggregates, 
before they can trigger the exponential proliferation brought about by secondary 
nucleation mechanisms. 
 
 
 
 
 
7.2 Results & Discussion 
 
We monitored the formation of amyloid aggregates by means of Thioflavin T 
(ThT) fluorescence [7.11, 7.12], following at the same time the conformational 
rearrangements of insulin molecules by their intrinsic tyrosine fluorescence2. Fig. 
7.1 reports the ThT (a) and the tyrosine (b) fluorescence signals as a function of 
time, during the fibrillation process (T = 60°C, insulin concentration 1 mg/ml), at 
different -cas concentrations. 
 
 
2The area of the emission bands corresponding to tyrosine (λmax ≃ 305 nm) and to ThT (λmax ≃ 485 nm) were extracted 
from each spectrum and plotted as a function of time to follow tertiary structure conformational changes (tyrosines) and 
amyloid formation (ThT) on the same sample. In fact, UV excitation (λex = 270 nm) allows to measure simultaneously both 
tyrosine and Thioflavin T emissions.  
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Figure 7.1 ThT (a) and tyrosine (b) fluorescence intensity as a function of time. The 
two fluorescence signals were measured contemporarily with an excitation wavelength of 
270 nm. Insulin concentration 1 mg/ml; T = 60 °C. Black: No casein; Red: casein 1:1000 
(mol:mol); Blue: 1:300; Pink: 1:100. 
 
 
 
 
 
 
In order to monitor at the same time the growth of amyloid aggregates and the 
accompanying conformational changes, we measured the two fluorescence signals 
during the same experiments, by exciting at the excitation wavelength of tyrosine 
(270 nm), which, as shown in Fig. 7.1a, is also able to produce ThT fluorescence 
(we remind that insulin has no tryptophans). This procedure lowers the resolution 
of the ThT fluorescence measurements, but allows the interesting comparison of 
the two signals[7.13]. ThT fluorescence data (Fig. 7.1a) clearly indicate that -cas 
has a strong, dose-dependent, inhibiting effect on the kinetics of insulin fibril 
formation, even at extremely low concentration. In fact, a ~10-fold lengthening in 
the initial lag-phase is produced by an -cas dose of 1:100 (molar ratio; insulin and 
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-cas have molecular weights of ~5800 and ~23000 Da, respectively). 
Interestingly, as shown in Fig. 7.1b, the presence of -cas induces a drastic 
reduction of tyrosine fluorescence intensity during the fibril formation process (the 
initial decrease in the fluorescence signal is due to the thermalization of the sample, 
from room temperature to 60 °C, which lowers the quantum yield of tyrosine 
independently from the fibrillation process). The different levels of tyrosine 
fluorescence quenching indicates that the presence of -cas not only strongly delays 
the fibrillation process, but also drives it toward different structures, which are 
probably characterized by a different solvent exposure of insulin tyrosine residues 
within the fibrils. The tyrosine fluorescence signal in Fig. 7.1b appears to diminish 
even before ThT fluorescence increase (Fig. 7.1a) especially for the sample at the 
highest -cas concentration. This could indicate the presence of conformational 
changes preceding the aggregation.  
We also investigated the changes in the tertiary structure of insulin during the 
fibrillation process by means of near UV Circular Dichroism (CD) spectroscopy, 
both in the absence and in the presence of 1:100 molar ratio of α-cas (Fig. 7.2, a 
and b respectively). Before the aggregation both samples display similar spectra 
(red curves in Fig. 7.2). However, the spectral alterations due to the fibrillation 
process are completely different in the two cases, thus confirming that the fibers 
formed in the presence of α-cas are different from those formed by insulin alone. 
The insert in Fig. 7.2b again puts in evidence the ~10-fold difference in the duration 
of the lag-phase, also evidencing that for both samples only negligible 
conformational changes seem to occur before aggregation. The morphology of the 
obtained fibrils was investigated by means of AFM microscopy (Fig. 7.2 c and d). 
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Figure 7.2 Panels a and b: Near UV Circular Dichroism spectra at different times 
during fibril formation of insulin (1 mg/ml), at 60 °C. (a) No casein; (b) casein 1:100 
(mol:mol). The insert in panel (b) shows the CD signal at 276 nm as a function of time for 
insulin alone (black) and for the sample with α-cas 1:100 (red).  Panels c and d: AFM 
images at the end of the fibril formation kinetics. (c) Insulin alone (after 1.5 h); (d) α-
cas 1:100 (after 8 h). 
 
 
 
Fibrils formed (after 8 h) in the presence of α-cas appear shorter, less ordered, 
and with a stronger propensity to stick together. The polymorphism of insulin fibrils 
is a well-known phenomenon.. Depending even on fine details of external 
parameters, insulin is able to form fibrils with different topology and 
properties[7.14, 7.15, 7.10, 7.16-7.19], which, in addition, seem to be able to self-
propagate in an amyloid strain mode [7.20-7.21]. In such conditions, it is perfectly 
reasonable that -cas, by affecting the initial nucleation stages of the process, also 
preferentially selects pathways to specific polymorphs. Furthermore, two insulin 
fibril polymorphs with unambiguously different surface exposure of tyrosine 
(c) 
 
(d) 
 
(d) 
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residues have been observed [7.22-7.24], which can help to explain the difference 
in the tyrosine fluorescence signal between our samples (Fig. 7.1b).  
To clarify the mechanisms of action of -cas, we also studied its effect on the 
thermal conformational rearrangements of insulin molecules. Fig. 7.3a, b reports 
Far-UV CD spectra obtained at different temperatures, from 10 to 70 °C at a rate 
20 °C/h, for insulin alone (a) and with -cas 1:100 (b). 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 CD spectra at different temperatures, from 10 (red curve) to 70 °C, for insulin 
alone (a) and with α-cas 1:100 (b). (c) DSC scan for insulin alone (black) and with α--
cas 1:100 (red); the insert in (c) shows the detail of the endothermic peak ascribable to 
conformational rearrangements. For all panels, insulin concentration is 1.0 mg/ml and scan 
rate is 20°C/h. 
 
As evident, α-cas has essentially no effect at all on the temperature induced 
secondary structure conformational change of insulin. This finding is also supported 
by differential scanning calorimetry (DSC) measurements (Figure 7.3c) performed 
under the same conditions. The presence of α-cas shifts to higher temperatures the 
exothermic peak brought about by the onset of the aggregation process, confirming 
its inhibiting effect; it also changes the enthalpy of aggregation peak from -108 to -
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-140 kJ/mol. On the contrary, in accordance with CD data (Fig. 7.3 a, b), it only 
slightly affects the broad endothermic peak observed at lower temperatures, which 
can be ascribed to temperature induced conformational changes. Also the enthalpy 
values for the endothermic peak are similar (11.2 kJ/mol for insulin alone and 
12.7 kJ/mol for the sample with α-cas). Data reported in Fig. 7.3 indicate that α-cas 
has no particular stabilizing effect on isolated protein molecules. Therefore, its 
mechanism of action probably concerns its interaction with aggregating species 
than with native proteins, as previously noted [7.25].  
Under our solvent conditions (HCl 25mM, NaCl 100mM, T = 60°C)  and at 
higher concentrations, insulin is known to display a biphasic fibrillation process, 
the first stage being the formation of relatively small, probably off-pathway[7.10], 
oligomers, which successively convert to fibrils4 [7.9]. As a consequence, we have 
here the possibility to study the inhibiting effect of α-cas against aggregation, 
ceteris paribus, for two processes with completely different phenomenology, by 
simply increasing the concentration of protein. Accordingly, we performed 
analogous experiments at a concentration of 5.0 mg/ml. Fig. 7.4a clearly shows the 
expected biphasic behavior, which is emphasized in the log-log plot of Fig. 7.4b. 
Moreover, Fig. 7.4b also shows that the portion of the kinetics relative to the 
formation of the oligomers follows quite well the ~t2 behavior (grey line) expected 
for an equilibrium nucleation dependent aggregation, without any secondary 
nucleation pathway [7.24, 7.26, 7.27, 7.29] α-cas has essentially no effect at all on 
the initial oligomer formation, while, on the contrary, still sizably retards the 
subsequent conversion of oligomers into fibrils. This completely different effect of 
α -cas on the two phases of the process leads to several interesting conclusions.  
 
 
 
 
 
 
 
 
4The formation of these oligomers proceeds immediately without any lag phase, and, at difference from the “standard” insulin 
amyloid fibrillation, does not show any evidence for the existence of secondary nucleation pathways. 
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Figure 7.4 ThT fluorescence intensity as a function of time (a) for insulin at a 
concentration of 5 mg/ml, T = 60°C. (b) Same data on a log-log scale. Black: No casein; 
Red: Casein 1:100 (mol:mol). The grey line in panel b represents a ~t2 behavior. 
 
 
Concerning the basic mechanisms underlying insulin fibrillation, data reported in 
Fig. 7.4 confirm that the oligomers initially formed at high protein concentration 
are not on-pathway with respect to fibrils formation. The most probable scenario is 
that the formation of oligomers is an independent process with respect to fibril 
formation and that it has a much stronger concentration dependence, thus resulting 
negligible at low concentration and significant at high concentration. Most likely, 
the oligomers initially formed are in equilibrium with monomers/dimers, whose 
addition to them is not irreversible, and the subsequent fibril growth proceeds by 
monomers/dimers release from the oligomers and association into fibrils. Only this 
last step results to be strongly affected by the presence of α-cas, even at strongly 
sub-stoichiometric concentration. 
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The previously described results indicate that (i) the second phase of the 
aggregation at high insulin concentration follows the same mechanisms observed 
in the low concentration regime, that is, primary and secondary nucleation, and (ii) 
concerning the chaperone-like activity of α-cas, a strong inhibiting effect is 
observed only when secondary nucleation plays an important role in the aggregation 
kinetics. On the contrary, there is no effect on the “ordinary” association of partially 
unfolded protein molecules, which leads to the formation of the oligomers. These 
observations help to clarify the mechanisms of action of α-cas. It is an intrinsically 
disordered protein, [7.28, 7.29] characterized by the presence of large hydrophobic 
regions, which make it able to polymerize and, together with other caseins, to form 
micellar structures [7.30]. Because of these properties, it can be able to sequester 
partially unfolded protein molecules and small aggregates exposing hydrophobic 
regions. Hence, when the primary nucleation is very slow and the kinetics of the 
aggregation is essentially determined by secondary nucleation mechanisms, as it is 
for insulin, [7.31-7.35] the capture of the early aggregates has a very strong effect 
because their growing is stopped before they become able to trigger the exponential 
proliferation of aggregates brought about by the secondary nucleation. This fact 
strongly increases the duration of the lag-phase observed in the low concentration 
regime, in a dose-dependent way, until a number of aggregation centers sufficient 
to saturate α-cas molecules is reached. Given the strongly sub-stoichiometric 
concentration, we believe that it is more plausible that α-cas is able to sequester a 
small amount of aggregates before they trigger secondary nucleation rather than 
promote a massive formation of oligomers in solution. Importantly, a strong sub-
stoichiometric effect has also been observed in the case of the Aβ1-40 peptide, 
[7.13] whose aggregation process is characterized by the presence of secondary 
nucleation mechanisms [7.36]. Consistent with the previously suggested 
mechanism of action, negligible effects have been found on the single-molecule 
conformational rearrangements under destabilizing conditions (Figure 7.3). It 
seems reasonable to extend this mechanism of action to other systems able to exert 
a “chaperone-like” activity against protein aggregation in a sub-stoichiometric 
concentration. [7.37, 7.38, 7.39] 
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7.3 Conclusions 
 
In conclusion, the study of the interactions between insulin and α-cas has shed new 
light both on the properties of insulin amyloid formation and on the mechanisms by 
which α-cas exerts its chaperone-like activity against aggregation. In particular, the 
connection here elucidated between the sub-stoichiometric effectiveness of α-cas 
and the presence of secondary nucleation pathways in the aggregation process of 
the target proteins may be an important and general feature in the activity of other 
chaperone-like molecules and could help to better understand the structural basis of 
the substrate binding in sHsps. Furthermore, it is worth to note that insulin, due to 
its use in diabetes treatments, has a considerable medical and commercial interest, 
and that α-cas is a quite cheap protein. Its strong effect on insulin aggregation, 
beyond the importance for the understanding of the molecular mechanisms of 
amyloid formation and its inhibition, may help to ameliorate insulin production 
processes, in which amyloid formation may represent a significant limit. 
 
 
 
 
 
 
The major part of the results discussed in this chapter are contained in the paper: 
 “α-Casein inhibits insulin amyloid formation by preventing the onset of secondary 
nucleation processes”, by Fabio Librizzi, Rita Carrotta, Dario Spigolon, Donatella 
Bulone, Pier Luigi San Biagio, published in The Journal of Physical Chemistry 
Letters, 5 (2014) 3034-3038, doi: 10.1021/jz501570m. 
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Conclusions 
 
In the last few years, chaperones appear to be emerging as a potential therapeutic 
strategy, particularly for the neurodegeneration field. Moreover, the growing 
number of diseases found to be linked to chaperone mutations, testifies to the 
importance of their role in the cellular protein-quality control mechanism 
(proteostasis).  
The investigation on the biophysical features of the interactions between specific 
chaperones and the specific protein structures involved in disease and the study of 
their structural and functional properties are a crucial basic step in order to validate 
their role in physiological and pathological state, and for the development of 
effective chaperones-based approaches. 
We investigated the (dis)assembly and thermal stability of chaperonins group I 
(mtHsp60, p-mtHsp60, GroEL) by means different biophysical techniques (DSC, 
ITC, CD, UV-vis, FCS, HPLC-SEC, DLS). Altogether, our findings suggest that 
the evolution of GroEL has generated such extreme cooperativity in unfolding in 
order to maximize its functional lifetime under harsh conditions. In turn, mtHsp60 
is less stable than GroEL and p-mtHp60, with a lower cooperativity in the thermal 
denaturation transition and a lower ∆Hd. 
This is due to a more versatility and flexibility of eukaryotic (particularly mtHsp60) 
proteins than prokaryotic, suggesting that subunit flexibility should be closely 
related to the evolutionary history of a complex. Moreover, our results suggests that 
GroEL and Hsp60s exist in a dynamic equilibrium between 
monomeric/heptameric/tetradecameric rings, and that the unfolding is coupled to 
the dissociation of the oligomeric protein.  
We believe that these studies in vitro of cooperativity, structural and thermal 
stability, on bacterial and human Hsp60 (across two proteins where these 
differences have functional relevance) could help to validate their role in 
physiological or pathological cases, and for the development of biomolecular 
nanocarriers, opening new possibilities for targeted drug delivery.  
Moreover, we studied the impact of a point mutation (His147Arg) in CCT5, one of 
the eight subunits of the chaperonin II (the human CCT/TRiC), upon the chaperones 
structure and functions. The mutation is multiplied eight-fold per ring compared to 
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the human CCT octamer. This amplification has proved instrumental for detecting 
subtle effects of a mutation, such as those which are likely to occur in humans, 
namely mutations that cause pathology but are compatible with survival. 
We observed a decreased stability and impaired chaperoning function in the 
hexadecamer formed by the mutant subunit and investigated on quantitative 
information on the loss of structural stability in the hexadecamer containing the 
pathogenic mutation. In conclusion, the chaperonin molecules tested (human w/wo 
mutation) have distinct thermodynamic profiles, showing different disassembly 
behavior and implying different cooperativity levels and different conformational 
trajectories. The pathogenic R mutant (named Pf-R) is energetically the weakest at 
maintaining the oligomeric complex and displays a distinct oligomeric equilibrium 
characterized by the lowest enthalpy of dissociation (∆Hd). Thus, the pathogenic 
mutation appears to reduce the protein's stability and its capacity for self-
organization. The observed differences in ATP binding provide further evidence 
that the R mutation in Pf-R disrupts the chaperonin's functional cycle by failing to 
induce the normal conformational changes. Pf-R has an exothermic ∆H (-26.8 
kcal/mol) compared to the endothermic values for the wild-type humanized version 
Pf-H (6.5 kcal/mol). 
This suggests that the pathology follows from a failure of ATP binding to induce 
the oligomer's closed conformation, which is required for ATP hydrolysis and the 
subsequent conformational cycling that underlies normal chaperonin function. 
Beyond the understanding of the basic mechanisms leading to amyloid formation, 
considerable efforts have been dedicated also to its inhibition, which can have 
important implications on medical, pharmaceutical and biotechnological research. 
In fact, amyloid formation, further than being involved in many diseases, may also 
represent a limit in protein purification, production and storage. 
Our results confirm the potential of molecular chaperones in interfering with the 
crucial molecular steps leading to amyloid aggregation in neurodegeneration and 
demonstrate that mtHsp60 is able to target the Aβ species responsible for induction 
of amyloid protein assembly. Due to the high grade of flexibility of the protein 
structure, mtHsp60 can interact with a very wide spectrum of biological molecules 
and protein conformations and with a high versatility of mechanisms of action, 
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exploiting as in the case of Hsp60 and Aβ oligomers, amateur, non-classical 
mechanisms.  
Among the inhibitors, milk casein proteins have been found to exert a chaperone-
like activity against aggregation. We found that an eﬃcient inhibition of amyloid 
formation can be achieved by chaperone-like systems, α-Caseins, which are able to 
exert a stabilizing function through direct interaction (similar to small Hsps), and 
we evaluated the mechanism of chaperone-like activity against aggregation. Our 
results indicate that inhibition of amyloid formation can be achieved by chaperone-
like systems by sequestering the early aggregates, before they can trigger the 
exponential proliferation brought about by secondary nucleation mechanisms. 
Investigation on its interaction mechanism could help to better understand the 
activity of other chaperone-like molecules and the structural basis of the substrate 
binding in sHsps. 
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Appendix 
Supplementary data 
A.1 FASTA sequences 
Pyrococcus furiosus (archaeal) CCT subunit: FASTA sequences 
Pyrococcus furiosus chaperonin (the archaeal Pf-Cpn). Ile (I) at position 138. 
>gi|18978346|ref|NP_579703.1| thermosome, single subunit [Pyrococcus furiosus DSM 3638]. 
Name: Pf-Cpn (549 amino acids). Note: this molecule was not studied in the work presented 
but it is shown here because it is the master molecule from which all studied mutants are 
derived. 
 
MAQLAGQPILILPEGTQRYVGRDAQRMNILAARIVAETIRTTLGPKGMDKMLVDSLGDIVI
TNDGATILDEMDIQHPAAKMMVEVAKTQDKEAGDGTTTAVVIAGELLRKAEELLDQNIH
PSIIIKGYTLAAQKAQEILENIAKEVKPDDEEILLKAAMTSITGKAAEEEREYLAKLAVEAV
KLVAEKEDGKYKVDIDNIKLEKKEGGSVRDTQLIRGVVIDKEVVHPGMPKRVEKAKIALI
NDALEVKETETDAEIRITSPEQLQAFLEQEERMLREMVEKIKEVGANVVFVQKGIDDLAQ
HYLAKYGIMAVRRVKKSDMEKLAKATGAKIVTNIRDLTPEDLGYAELVEERKVAGESMI
FVEGCQNPKAVTILIRGGTEHVVDEVERALEDAIKVVKDILEDGKILAGGGAPEIELAIRLD
EYAKEVGGKEQLAIEAFAEALKVIPRTLAENAGLDPIETLVKVIAAHKEKGPTIGVDVYEG
EPADMLERGVIEPLRVKKQAIKSASEAAIMILRIDDVIAASKLEKEKEKEGEKGGGSEDF
SSDLD 
 
Mutants studied 
Pyrococcus furiosus chaperonin Pf-Cpn mutant CD1, namely the wild type without the last 
22 amino acids  
Name: Pf-CD1. (527 amino acids). 
 
MAQLAGQPILILPEGTQRYVGRDAQRMNILAARIVAETIRTTLGPKGMDKMLVDSLGDIVI
TNDGATILDEMDIQHPAAKMMVEVAKTQDKEAGDGTTTAVVIAGELLRKAEELLDQNIH
PSIIIKGYTLAAQKAQEILENIAKEVKPDDEEILLKAAMTSITGKAAEEEREYLAKLAVEAV
KLVAEKEDGKYKVDIDNIKLEKKEGGSVRDTQLIRGVVIDKEVVHPGMPKRVEKAKIALI
NDALEVKETETDAEIRITSPEQLQAFLEQEERMLREMVEKIKEVGANVVFVQKGIDDLAQ
HYLAKYGIMAVRRVKKSDMEKLAKATGAKIVTNIRDLTPEDLGYAELVEERKVAGESMI
FVEGCQNPKAVTILIRGGTEHVVDEVERALEDAIKVVKDILEDGKILAGGGAPEIELAIRLD
EYAKEVGGKEQLAIEAFAEALKVIPRTLAENAGLDPIETLVKVIAAHKEKGPTIGVDVYEG
EPADMLERGVIEPLRVKKQAIKSASEAAIMILRIDDVIAASKL 
 
 
 
 
 
 Dario Spigolon 
 
148 Biophysical investigation on therapeutic proteins (Chaperonins, Hsp60 and CCT/TRiC) involved in human diseases 
Pyrococcus furiosus chaperonin Pf-Cpn mutant CD1, namely the wild type without the last 
22 amino acids, with His (H) instead of Ile at position 138 (Ile138His).  
Name: Pf-CD1 His 138; Pf-H in short. (527 amino acids). 
 
MAQLAGQPILILPEGTQRYVGRDAQRMNILAARIVAETIRTTLGPKGMDKMLVDSLGDIVI
TNDGATILDEMDIQHPAAKMMVEVAKTQDKEAGDGTTTAVVIAGELLRKAEELLDQNIH
PSIIIKGYTLAAQKAQEHLENIAKEVKPDDEEILLKAAMTSITGKAAEEEREYLAKLAVEA
VKLVAEKEDGKYKVDIDNIKLEKKEGGSVRDTQLIRGVVIDKEVVHPGMPKRVEKAKIAL
INDALEVKETETDAEIRITSPEQLQAFLEQEERMLREMVEKIKEVGANVVFVQKGIDDLAQ
HYLAKYGIMAVRRVKKSDMEKLAKATGAKIVTNIRDLTPEDLGYAELVEERKVAGESMI
FVEGCQNPKAVTILIRGGTEHVVDEVERALEDAIKVVKDILEDGKILAGGGAPEIELAIRLD
EYAKEVGGKEQLAIEAFAEALKVIPRTLAENAGLDPIETLVKVIAAHKEKGPTIGVDVYEG
EPADMLERGVIEPLRVKKQAIKSASEAAIMILRIDDVIAASKL 
 
Pyrococcus furiosus chaperonin Pf-Cpn mutant CD1, namely the wild type without the last 
22 amino acids, with Arg (R)instead of Ile or His at position 138 (Ile148Arg).  
Name: Pf-CD1 Arg 138; Pf-R in short. (527 amino acids). 
 
MAQLAGQPILILPEGTQRYVGRDAQRMNILAARIVAETIRTTLGPKGMDKMLVDSLGDIVI
TNDGATILDEMDIQHPAAKMMVEVAKTQDKEAGDGTTTAVVIAGELLRKAEELLDQNIH
PSIIIKGYTLAAQKAQERLENIAKEVKPDDEEILLKAAMTSITGKAAEEEREYLAKLAVEA
VKLVAEKEDGKYKVDIDNIKLEKKEGGSVRDTQLIRGVVIDKEVVHPGMPKRVEKAKIAL
INDALEVKETETDAEIRITSPEQLQAFLEQEERMLREMVEKIKEVGANVVFVQKGIDDLAQ
HYLAKYGIMAVRRVKKSDMEKLAKATGAKIVTNIRDLTPEDLGYAELVEERKVAGESMI
FVEGCQNPKAVTILIRGGTEHVVDEVERALEDAIKVVKDILEDGKILAGGGAPEIELAIRLD
EYAKEVGGKEQLAIEAFAEALKVIPRTLAENAGLDPIETLVKVIAAHKEKGPTIGVDVYEG
EPADMLERGVIEPLRVKKQAIKSASEAAIMILRIDDVIAASKL 
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A.2 Nucleotide effect on Pf-CD1, Pf-H, Pf-R 
 
Secondary structure composition and assignments from Circula Dichroism spectra 
for native and upon the binding with ATP 
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